# PeptideScanner evidence objects: Bivalirudin

Every published version of the records placed with Bivalirudin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json. Selected public evidence only; not medical advice.

- Objects: 78
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00043940-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00043940

> PeptideScanner retained ClinicalTrials.gov record NCT00043940 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-09-16, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00043940-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-09-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00043940-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00043940-bivalirudin-v1
- Content SHA-256: `e1a5f05b96fa108551e007487a0fb47ed83d5340d4edf1ab8100c58e8d038fcb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00043940 ([`ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98`](#source-ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00043940 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-09-16, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98`](#source-ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00043940 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-09-16, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98`](#source-ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98`](#source-ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98))

### Sources

<a id="source-ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98"></a>
- **ClinicalTrials.gov record NCT00043940 · retained source version 2011-09-16:2b0bd4adbe983b7c2ba0106d8f29a8c880e4360154296e7773080cb3dc5b9f3a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00043940) (`ctg-observation-nct00043940-2011-09-16-2b0bd4adbe98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00043940." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00043940-bivalirudin-v1 SHA-256: e1a5f05b96fa108551e007487a0fb47ed83d5340d4edf1ab8100c58e8d038fcb.

---

<a id="clinicaltrials-gov-nct00073580-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00073580

> PeptideScanner retained ClinicalTrials.gov record NCT00073580 at 2026-11-15T21:58:19.888Z. Its registry update date was 2018-11-30, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00073580-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00073580-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00073580-bivalirudin-v1
- Content SHA-256: `6463eb00683edd3f7b7b53608989dbb685e35d649fa16f548132d52c3823bdd3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00073580 ([`ctg-observation-nct00073580-2018-11-30-1a247606ad84`](#source-ctg-observation-nct00073580-2018-11-30-1a247606ad84))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00073580 at 2026-11-15T21:58:19.888Z. Its registry update date was 2018-11-30, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00073580-2018-11-30-1a247606ad84`](#source-ctg-observation-nct00073580-2018-11-30-1a247606ad84))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00073580 at 2026-11-15T21:58:19.888Z. Its registry update date was 2018-11-30, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00073580-2018-11-30-1a247606ad84`](#source-ctg-observation-nct00073580-2018-11-30-1a247606ad84))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00073580-2018-11-30-1a247606ad84`](#source-ctg-observation-nct00073580-2018-11-30-1a247606ad84))

### Sources

<a id="source-ctg-observation-nct00073580-2018-11-30-1a247606ad84"></a>
- **ClinicalTrials.gov record NCT00073580 · retained source version 2018-11-30:1a247606ad843e8030a7d2e405be5c8b8eebeac769246a4056a2f1ec5c100440** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00073580) (`ctg-observation-nct00073580-2018-11-30-1a247606ad84`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00073580." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00073580-bivalirudin-v1 SHA-256: 6463eb00683edd3f7b7b53608989dbb685e35d649fa16f548132d52c3823bdd3.

---

<a id="clinicaltrials-gov-nct00073593-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00073593

> PeptideScanner retained ClinicalTrials.gov record NCT00073593 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00073593-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-11-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00073593-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00073593-bivalirudin-v1
- Content SHA-256: `b0bf2316a44ec1361e9d509a89433c484f0f1d60632cf32612653560035f8d77`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00073593 ([`ctg-observation-nct00073593-2011-11-10-bc509b591b4a`](#source-ctg-observation-nct00073593-2011-11-10-bc509b591b4a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00073593 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00073593-2011-11-10-bc509b591b4a`](#source-ctg-observation-nct00073593-2011-11-10-bc509b591b4a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00073593 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00073593-2011-11-10-bc509b591b4a`](#source-ctg-observation-nct00073593-2011-11-10-bc509b591b4a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00073593-2011-11-10-bc509b591b4a`](#source-ctg-observation-nct00073593-2011-11-10-bc509b591b4a))

### Sources

<a id="source-ctg-observation-nct00073593-2011-11-10-bc509b591b4a"></a>
- **ClinicalTrials.gov record NCT00073593 · retained source version 2011-11-10:bc509b591b4ae6fe5a74ad9ad4de3065876bd5aac88a67a81289821c8195a04c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00073593) (`ctg-observation-nct00073593-2011-11-10-bc509b591b4a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00073593." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00073593-bivalirudin-v1 SHA-256: b0bf2316a44ec1361e9d509a89433c484f0f1d60632cf32612653560035f8d77.

---

<a id="clinicaltrials-gov-nct00079586-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00079586

> PeptideScanner retained ClinicalTrials.gov record NCT00079586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-01-05, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00079586-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-01-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00079586-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00079586-bivalirudin-v1
- Content SHA-256: `af8beb43c5bb69b3b0f7d8bddeaec6d20fd428f7e3b47e29591b425b53e78d82`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00079586 ([`ctg-observation-nct00079586-2012-01-05-7d89db766949`](#source-ctg-observation-nct00079586-2012-01-05-7d89db766949))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00079586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-01-05, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00079586-2012-01-05-7d89db766949`](#source-ctg-observation-nct00079586-2012-01-05-7d89db766949))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00079586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-01-05, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00079586-2012-01-05-7d89db766949`](#source-ctg-observation-nct00079586-2012-01-05-7d89db766949))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00079586-2012-01-05-7d89db766949`](#source-ctg-observation-nct00079586-2012-01-05-7d89db766949))

### Sources

<a id="source-ctg-observation-nct00079586-2012-01-05-7d89db766949"></a>
- **ClinicalTrials.gov record NCT00079586 · retained source version 2012-01-05:7d89db76694926706399606155e45aa77ff90968fdb1ea991436f910c85b612e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00079586) (`ctg-observation-nct00079586-2012-01-05-7d89db766949`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00079586." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00079586-bivalirudin-v1 SHA-256: af8beb43c5bb69b3b0f7d8bddeaec6d20fd428f7e3b47e29591b425b53e78d82.

---

<a id="clinicaltrials-gov-nct00262054-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00262054

> PeptideScanner retained ClinicalTrials.gov record NCT00262054 at 2026-11-15T21:58:19.888Z. Its registry update date was 2010-03-15, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00262054-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-03-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00262054-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00262054-bivalirudin-v1
- Content SHA-256: `3ea7221eb3f4e3696f658e55490e0eb2dbd212885c57522774aabfd1a2bc84cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00262054 ([`ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e`](#source-ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00262054 at 2026-11-15T21:58:19.888Z. Its registry update date was 2010-03-15, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e`](#source-ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00262054 at 2026-11-15T21:58:19.888Z. Its registry update date was 2010-03-15, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e`](#source-ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e`](#source-ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e))

### Sources

<a id="source-ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e"></a>
- **ClinicalTrials.gov record NCT00262054 · retained source version 2010-03-15:81a0b14b8a1e69fe63a34b66896eeef0cf17636f962e6309c8bedc390a522e9a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00262054) (`ctg-observation-nct00262054-2010-03-15-81a0b14b8a1e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00262054." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00262054-bivalirudin-v1 SHA-256: 3ea7221eb3f4e3696f658e55490e0eb2dbd212885c57522774aabfd1a2bc84cd.

---

<a id="clinicaltrials-gov-nct00373451-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00373451

> PeptideScanner retained ClinicalTrials.gov record NCT00373451 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00373451-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-05-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00373451-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00373451-bivalirudin-v1
- Content SHA-256: `57d3fd987abf4287a3072b605109a48af37bd0073b4d5c40418be9b2029428e3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00373451 ([`ctg-observation-nct00373451-2012-05-08-41a1e7741488`](#source-ctg-observation-nct00373451-2012-05-08-41a1e7741488))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00373451 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00373451-2012-05-08-41a1e7741488`](#source-ctg-observation-nct00373451-2012-05-08-41a1e7741488))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00373451 at 2026-11-15T21:58:19.888Z. Its registry update date was 2012-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00373451-2012-05-08-41a1e7741488`](#source-ctg-observation-nct00373451-2012-05-08-41a1e7741488))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00373451-2012-05-08-41a1e7741488`](#source-ctg-observation-nct00373451-2012-05-08-41a1e7741488))

### Sources

<a id="source-ctg-observation-nct00373451-2012-05-08-41a1e7741488"></a>
- **ClinicalTrials.gov record NCT00373451 · retained source version 2012-05-08:41a1e77414880afd2a8cae6a056723b64d65b70d8646663b2accfe91fe010054** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00373451) (`ctg-observation-nct00373451-2012-05-08-41a1e7741488`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00373451." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00373451-bivalirudin-v1 SHA-256: 57d3fd987abf4287a3072b605109a48af37bd0073b4d5c40418be9b2029428e3.

---

<a id="clinicaltrials-gov-nct00433966-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00433966

> PeptideScanner retained ClinicalTrials.gov record NCT00433966 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-12-04, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00433966-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00433966-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00433966-bivalirudin-v1
- Content SHA-256: `8722325d5d08e428ba530276606dff0e53bf3f6bbb442c4748244bdb2677dcf3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00433966 ([`ctg-observation-nct00433966-2017-12-04-1e492b249cd8`](#source-ctg-observation-nct00433966-2017-12-04-1e492b249cd8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00433966 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-12-04, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00433966-2017-12-04-1e492b249cd8`](#source-ctg-observation-nct00433966-2017-12-04-1e492b249cd8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00433966 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-12-04, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00433966-2017-12-04-1e492b249cd8`](#source-ctg-observation-nct00433966-2017-12-04-1e492b249cd8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00433966-2017-12-04-1e492b249cd8`](#source-ctg-observation-nct00433966-2017-12-04-1e492b249cd8))

### Sources

<a id="source-ctg-observation-nct00433966-2017-12-04-1e492b249cd8"></a>
- **ClinicalTrials.gov record NCT00433966 · retained source version 2017-12-04:1e492b249cd8a1358ac113badaa02d05f70b8aa08912ecb293fc74711e30f23a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00433966) (`ctg-observation-nct00433966-2017-12-04-1e492b249cd8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00433966." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00433966-bivalirudin-v1 SHA-256: 8722325d5d08e428ba530276606dff0e53bf3f6bbb442c4748244bdb2677dcf3.

---

<a id="clinicaltrials-gov-nct00448461-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00448461

> PeptideScanner retained ClinicalTrials.gov record NCT00448461 at 2026-11-15T21:58:19.888Z. Its registry update date was 2009-02-10, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00448461-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-02-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00448461-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00448461-bivalirudin-v1
- Content SHA-256: `ed2a399710a8fb3a73622618ce896be4bd7fb71c74919603a3052333554d5a9a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00448461 ([`ctg-observation-nct00448461-2009-02-10-f6474960dec1`](#source-ctg-observation-nct00448461-2009-02-10-f6474960dec1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00448461 at 2026-11-15T21:58:19.888Z. Its registry update date was 2009-02-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00448461-2009-02-10-f6474960dec1`](#source-ctg-observation-nct00448461-2009-02-10-f6474960dec1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00448461 at 2026-11-15T21:58:19.888Z. Its registry update date was 2009-02-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00448461-2009-02-10-f6474960dec1`](#source-ctg-observation-nct00448461-2009-02-10-f6474960dec1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00448461-2009-02-10-f6474960dec1`](#source-ctg-observation-nct00448461-2009-02-10-f6474960dec1))

### Sources

<a id="source-ctg-observation-nct00448461-2009-02-10-f6474960dec1"></a>
- **ClinicalTrials.gov record NCT00448461 · retained source version 2009-02-10:f6474960dec195cdc530c245b1263493090316d001ec36caacae08ae070cde50** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00448461) (`ctg-observation-nct00448461-2009-02-10-f6474960dec1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00448461." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00448461-bivalirudin-v1 SHA-256: ed2a399710a8fb3a73622618ce896be4bd7fb71c74919603a3052333554d5a9a.

---

<a id="clinicaltrials-gov-nct00503126-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00503126

> PeptideScanner retained ClinicalTrials.gov record NCT00503126 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00503126-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-11-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00503126-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00503126-bivalirudin-v1
- Content SHA-256: `bbd8794b8be25b72500a04e740fb0d79a30bebfc98c6c78795e09da4909a5267`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00503126 ([`ctg-observation-nct00503126-2011-11-10-ea85ea6fac85`](#source-ctg-observation-nct00503126-2011-11-10-ea85ea6fac85))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00503126 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00503126-2011-11-10-ea85ea6fac85`](#source-ctg-observation-nct00503126-2011-11-10-ea85ea6fac85))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00503126 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00503126-2011-11-10-ea85ea6fac85`](#source-ctg-observation-nct00503126-2011-11-10-ea85ea6fac85))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00503126-2011-11-10-ea85ea6fac85`](#source-ctg-observation-nct00503126-2011-11-10-ea85ea6fac85))

### Sources

<a id="source-ctg-observation-nct00503126-2011-11-10-ea85ea6fac85"></a>
- **ClinicalTrials.gov record NCT00503126 · retained source version 2011-11-10:ea85ea6fac85c313ad44ecb834ac9b6dca5205a49b1caaa874984fdbfbe1a332** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00503126) (`ctg-observation-nct00503126-2011-11-10-ea85ea6fac85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00503126." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00503126-bivalirudin-v1 SHA-256: bbd8794b8be25b72500a04e740fb0d79a30bebfc98c6c78795e09da4909a5267.

---

<a id="clinicaltrials-gov-nct00616460-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00616460

> PeptideScanner retained ClinicalTrials.gov record NCT00616460 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-06-12, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00616460-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-06-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00616460-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00616460-bivalirudin-v1
- Content SHA-256: `bd04a2d5c1fcc42acc821a305add7e2e9be7d2fff6941e398fd5c32a56ea62d6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00616460 ([`ctg-observation-nct00616460-2015-06-12-bc70293a3c76`](#source-ctg-observation-nct00616460-2015-06-12-bc70293a3c76))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00616460 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-06-12, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00616460-2015-06-12-bc70293a3c76`](#source-ctg-observation-nct00616460-2015-06-12-bc70293a3c76))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00616460 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-06-12, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00616460-2015-06-12-bc70293a3c76`](#source-ctg-observation-nct00616460-2015-06-12-bc70293a3c76))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00616460-2015-06-12-bc70293a3c76`](#source-ctg-observation-nct00616460-2015-06-12-bc70293a3c76))

### Sources

<a id="source-ctg-observation-nct00616460-2015-06-12-bc70293a3c76"></a>
- **ClinicalTrials.gov record NCT00616460 · retained source version 2015-06-12:bc70293a3c76cff889c43691fafe71a77513642ad9b38f9d3dc2e85bbdaa616a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00616460) (`ctg-observation-nct00616460-2015-06-12-bc70293a3c76`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00616460." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00616460-bivalirudin-v1 SHA-256: bd04a2d5c1fcc42acc821a305add7e2e9be7d2fff6941e398fd5c32a56ea62d6.

---

<a id="clinicaltrials-gov-nct00812370-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT00812370

> PeptideScanner retained ClinicalTrials.gov record NCT00812370 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct00812370-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00812370-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00812370-bivalirudin-v1
- Content SHA-256: `0b7801be18d7f3d849c4dfe0838ec4ae34ac6d7ffa5ee450ed0db36d116d5197`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00812370 ([`ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b`](#source-ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00812370 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b`](#source-ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00812370 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b`](#source-ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b`](#source-ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b))

### Sources

<a id="source-ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b"></a>
- **ClinicalTrials.gov record NCT00812370 · retained source version 2016-07-15:fc5b2f22a38bea6c72a0baf156ab0074608602f94dff09f895014e718d9f0038** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00812370) (`ctg-observation-nct00812370-2016-07-15-fc5b2f22a38b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00812370." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct00812370-bivalirudin-v1 SHA-256: 0b7801be18d7f3d849c4dfe0838ec4ae34ac6d7ffa5ee450ed0db36d116d5197.

---

<a id="clinicaltrials-gov-nct01087723-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT01087723

> PeptideScanner retained ClinicalTrials.gov record NCT01087723 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-02-12, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct01087723-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-02-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01087723-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01087723-bivalirudin-v1
- Content SHA-256: `3da5403d17819cc99fdc8a9386393e5c356d1500736c7a1d6c75a6cc965dd449`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01087723 ([`ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf`](#source-ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01087723 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-02-12, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf`](#source-ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01087723 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-02-12, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf`](#source-ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf`](#source-ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf))

### Sources

<a id="source-ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf"></a>
- **ClinicalTrials.gov record NCT01087723 · retained source version 2016-02-12:f5fb37e6d6bfb530383a3ec135e2679604882be1d07d64236662d5ca2297eac1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01087723) (`ctg-observation-nct01087723-2016-02-12-f5fb37e6d6bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01087723." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01087723-bivalirudin-v1 SHA-256: 3da5403d17819cc99fdc8a9386393e5c356d1500736c7a1d6c75a6cc965dd449.

---

<a id="clinicaltrials-gov-nct01465503-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT01465503

> PeptideScanner retained ClinicalTrials.gov record NCT01465503 at 2026-11-15T21:58:19.888Z. Its registry update date was 2014-04-08, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct01465503-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-04-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01465503-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01465503-bivalirudin-v1
- Content SHA-256: `6cadacddd0f80c010d67d65cdea1c8910dc2dfa65fcff00f8130753ffa070573`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01465503 ([`ctg-observation-nct01465503-2014-04-08-78fcf1564ccc`](#source-ctg-observation-nct01465503-2014-04-08-78fcf1564ccc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01465503 at 2026-11-15T21:58:19.888Z. Its registry update date was 2014-04-08, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01465503-2014-04-08-78fcf1564ccc`](#source-ctg-observation-nct01465503-2014-04-08-78fcf1564ccc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01465503 at 2026-11-15T21:58:19.888Z. Its registry update date was 2014-04-08, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01465503-2014-04-08-78fcf1564ccc`](#source-ctg-observation-nct01465503-2014-04-08-78fcf1564ccc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01465503-2014-04-08-78fcf1564ccc`](#source-ctg-observation-nct01465503-2014-04-08-78fcf1564ccc))

### Sources

<a id="source-ctg-observation-nct01465503-2014-04-08-78fcf1564ccc"></a>
- **ClinicalTrials.gov record NCT01465503 · retained source version 2014-04-08:78fcf1564ccc286ae74f028cf87ca18968fe04722120b2d7adab4c565427d285** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01465503) (`ctg-observation-nct01465503-2014-04-08-78fcf1564ccc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01465503." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01465503-bivalirudin-v1 SHA-256: 6cadacddd0f80c010d67d65cdea1c8910dc2dfa65fcff00f8130753ffa070573.

---

<a id="clinicaltrials-gov-nct01519518-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT01519518

> PeptideScanner retained ClinicalTrials.gov record NCT01519518 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-05-13, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct01519518-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-05-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01519518-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01519518-bivalirudin-v1
- Content SHA-256: `91450ca0b262cdf05c49404c3a245782f69d7af67c9d39f06ac8897599b87b1e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01519518 ([`ctg-observation-nct01519518-2015-05-13-088045807792`](#source-ctg-observation-nct01519518-2015-05-13-088045807792))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01519518 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-05-13, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01519518-2015-05-13-088045807792`](#source-ctg-observation-nct01519518-2015-05-13-088045807792))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01519518 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-05-13, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01519518-2015-05-13-088045807792`](#source-ctg-observation-nct01519518-2015-05-13-088045807792))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01519518-2015-05-13-088045807792`](#source-ctg-observation-nct01519518-2015-05-13-088045807792))

### Sources

<a id="source-ctg-observation-nct01519518-2015-05-13-088045807792"></a>
- **ClinicalTrials.gov record NCT01519518 · retained source version 2015-05-13:0880458077923c3a9040f3d558266cee58841ca6ad0ee57d30687392b02a1873** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01519518) (`ctg-observation-nct01519518-2015-05-13-088045807792`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01519518." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01519518-bivalirudin-v1 SHA-256: 91450ca0b262cdf05c49404c3a245782f69d7af67c9d39f06ac8897599b87b1e.

---

<a id="clinicaltrials-gov-nct01651780-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT01651780

> PeptideScanner retained ClinicalTrials.gov record NCT01651780 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct01651780-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01651780-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01651780-bivalirudin-v1
- Content SHA-256: `b0d5b03a9adcb3f97b9a238f37effbf7d0de0659a900792f923501d3fa047b37`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01651780 ([`ctg-observation-nct01651780-2017-04-07-b504cd7ab08c`](#source-ctg-observation-nct01651780-2017-04-07-b504cd7ab08c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01651780 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01651780-2017-04-07-b504cd7ab08c`](#source-ctg-observation-nct01651780-2017-04-07-b504cd7ab08c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01651780 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01651780-2017-04-07-b504cd7ab08c`](#source-ctg-observation-nct01651780-2017-04-07-b504cd7ab08c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01651780-2017-04-07-b504cd7ab08c`](#source-ctg-observation-nct01651780-2017-04-07-b504cd7ab08c))

### Sources

<a id="source-ctg-observation-nct01651780-2017-04-07-b504cd7ab08c"></a>
- **ClinicalTrials.gov record NCT01651780 · retained source version 2017-04-07:b504cd7ab08c9f71deb3e16a5267e54e34edbb313a7d328081a3ad96d80b6357** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01651780) (`ctg-observation-nct01651780-2017-04-07-b504cd7ab08c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01651780." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01651780-bivalirudin-v1 SHA-256: b0d5b03a9adcb3f97b9a238f37effbf7d0de0659a900792f923501d3fa047b37.

---

<a id="clinicaltrials-gov-nct01848899-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT01848899

> PeptideScanner retained ClinicalTrials.gov record NCT01848899 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct01848899-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01848899-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01848899-bivalirudin-v1
- Content SHA-256: `10ef76ec2b94e53207820a353ed658865e044f183f69339ba95f1aac54c5a38d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01848899 ([`ctg-observation-nct01848899-2016-04-06-b8de49864dde`](#source-ctg-observation-nct01848899-2016-04-06-b8de49864dde))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01848899 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01848899-2016-04-06-b8de49864dde`](#source-ctg-observation-nct01848899-2016-04-06-b8de49864dde))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01848899 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct01848899-2016-04-06-b8de49864dde`](#source-ctg-observation-nct01848899-2016-04-06-b8de49864dde))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01848899-2016-04-06-b8de49864dde`](#source-ctg-observation-nct01848899-2016-04-06-b8de49864dde))

### Sources

<a id="source-ctg-observation-nct01848899-2016-04-06-b8de49864dde"></a>
- **ClinicalTrials.gov record NCT01848899 · retained source version 2016-04-06:b8de49864dde3334e3a775b94e4e8c94a50d72f7266ae057c5f3198bf70dd6ba** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01848899) (`ctg-observation-nct01848899-2016-04-06-b8de49864dde`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01848899." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct01848899-bivalirudin-v1 SHA-256: 10ef76ec2b94e53207820a353ed658865e044f183f69339ba95f1aac54c5a38d.

---

<a id="clinicaltrials-gov-nct02311231-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT02311231

> PeptideScanner retained ClinicalTrials.gov record NCT02311231 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-05-19, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct02311231-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02311231-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct02311231-bivalirudin-v1
- Content SHA-256: `7dbe62f222f244d1ce1874bb30c03d5ddd3d7e9ddfd2048538cb617084421d2a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02311231 ([`ctg-observation-nct02311231-2017-05-19-ba56c8fda91b`](#source-ctg-observation-nct02311231-2017-05-19-ba56c8fda91b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02311231 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-05-19, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct02311231-2017-05-19-ba56c8fda91b`](#source-ctg-observation-nct02311231-2017-05-19-ba56c8fda91b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02311231 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-05-19, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct02311231-2017-05-19-ba56c8fda91b`](#source-ctg-observation-nct02311231-2017-05-19-ba56c8fda91b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02311231-2017-05-19-ba56c8fda91b`](#source-ctg-observation-nct02311231-2017-05-19-ba56c8fda91b))

### Sources

<a id="source-ctg-observation-nct02311231-2017-05-19-ba56c8fda91b"></a>
- **ClinicalTrials.gov record NCT02311231 · retained source version 2017-05-19:ba56c8fda91b57240463fe0565dc411de4a34373aabbacd4d1e25829a97f8805** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02311231) (`ctg-observation-nct02311231-2017-05-19-ba56c8fda91b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02311231." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct02311231-bivalirudin-v1 SHA-256: 7dbe62f222f244d1ce1874bb30c03d5ddd3d7e9ddfd2048538cb617084421d2a.

---

<a id="clinicaltrials-gov-nct02384070-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT02384070

> PeptideScanner retained ClinicalTrials.gov record NCT02384070 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-02-03, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct02384070-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02384070-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct02384070-bivalirudin-v1
- Content SHA-256: `c9ee772dd7a98daacef506413e205d79bca3b1225bbf4da41f59d72b755ab78c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02384070 ([`ctg-observation-nct02384070-2017-02-03-c7ea3730aed6`](#source-ctg-observation-nct02384070-2017-02-03-c7ea3730aed6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02384070 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-02-03, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct02384070-2017-02-03-c7ea3730aed6`](#source-ctg-observation-nct02384070-2017-02-03-c7ea3730aed6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02384070 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-02-03, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct02384070-2017-02-03-c7ea3730aed6`](#source-ctg-observation-nct02384070-2017-02-03-c7ea3730aed6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02384070-2017-02-03-c7ea3730aed6`](#source-ctg-observation-nct02384070-2017-02-03-c7ea3730aed6))

### Sources

<a id="source-ctg-observation-nct02384070-2017-02-03-c7ea3730aed6"></a>
- **ClinicalTrials.gov record NCT02384070 · retained source version 2017-02-03:c7ea3730aed67e13aa82076cfb21e0e7f9576fc83f50c8d128722773df47b92c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02384070) (`ctg-observation-nct02384070-2017-02-03-c7ea3730aed6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02384070." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct02384070-bivalirudin-v1 SHA-256: c9ee772dd7a98daacef506413e205d79bca3b1225bbf4da41f59d72b755ab78c.

---

<a id="clinicaltrials-gov-nct03318393-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT03318393

> PeptideScanner retained ClinicalTrials.gov record NCT03318393 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-01-31, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct03318393-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03318393-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03318393-bivalirudin-v1
- Content SHA-256: `e756fb72292b3e6eea3acbd1c35947bf203b03651ba5a5f163e124586e906929`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03318393 ([`ctg-observation-nct03318393-2023-01-31-838dcd5f27af`](#source-ctg-observation-nct03318393-2023-01-31-838dcd5f27af))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03318393 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-01-31, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03318393-2023-01-31-838dcd5f27af`](#source-ctg-observation-nct03318393-2023-01-31-838dcd5f27af))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03318393 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-01-31, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03318393-2023-01-31-838dcd5f27af`](#source-ctg-observation-nct03318393-2023-01-31-838dcd5f27af))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03318393-2023-01-31-838dcd5f27af`](#source-ctg-observation-nct03318393-2023-01-31-838dcd5f27af))

### Sources

<a id="source-ctg-observation-nct03318393-2023-01-31-838dcd5f27af"></a>
- **ClinicalTrials.gov record NCT03318393 · retained source version 2023-01-31:838dcd5f27afb8cf49cba63ccaa694ba5e5a9230f0b37c8c20e715aa3fac7188** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03318393) (`ctg-observation-nct03318393-2023-01-31-838dcd5f27af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03318393." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03318393-bivalirudin-v1 SHA-256: e756fb72292b3e6eea3acbd1c35947bf203b03651ba5a5f163e124586e906929.

---

<a id="clinicaltrials-gov-nct03532399-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT03532399

> PeptideScanner retained ClinicalTrials.gov record NCT03532399 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct03532399-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03532399-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03532399-bivalirudin-v1
- Content SHA-256: `4fa9dbfcb78a5318cdbf4b802eccef2c72b93b312484e3d7b449e81e27cb5854`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03532399 ([`ctg-observation-nct03532399-2025-07-02-661733031f0b`](#source-ctg-observation-nct03532399-2025-07-02-661733031f0b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03532399 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03532399-2025-07-02-661733031f0b`](#source-ctg-observation-nct03532399-2025-07-02-661733031f0b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03532399 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03532399-2025-07-02-661733031f0b`](#source-ctg-observation-nct03532399-2025-07-02-661733031f0b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03532399-2025-07-02-661733031f0b`](#source-ctg-observation-nct03532399-2025-07-02-661733031f0b))

### Sources

<a id="source-ctg-observation-nct03532399-2025-07-02-661733031f0b"></a>
- **ClinicalTrials.gov record NCT03532399 · retained source version 2025-07-02:661733031f0bf499251d9c30aad49e1f20969f2f4ef68eae8f685936d85f0105** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03532399) (`ctg-observation-nct03532399-2025-07-02-661733031f0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03532399." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03532399-bivalirudin-v1 SHA-256: 4fa9dbfcb78a5318cdbf4b802eccef2c72b93b312484e3d7b449e81e27cb5854.

---

<a id="clinicaltrials-gov-nct03537586-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT03537586

> PeptideScanner retained ClinicalTrials.gov record NCT03537586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct03537586-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03537586-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03537586-bivalirudin-v1
- Content SHA-256: `a0311d3687743ff8aa1c0ff8755fd472f77684ad5fb296e2200091852265c0ea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03537586 ([`ctg-observation-nct03537586-2026-11-04-db1a1899c7ca`](#source-ctg-observation-nct03537586-2026-11-04-db1a1899c7ca))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03537586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03537586-2026-11-04-db1a1899c7ca`](#source-ctg-observation-nct03537586-2026-11-04-db1a1899c7ca))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03537586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03537586-2026-11-04-db1a1899c7ca`](#source-ctg-observation-nct03537586-2026-11-04-db1a1899c7ca))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03537586-2026-11-04-db1a1899c7ca`](#source-ctg-observation-nct03537586-2026-11-04-db1a1899c7ca))

### Sources

<a id="source-ctg-observation-nct03537586-2026-11-04-db1a1899c7ca"></a>
- **ClinicalTrials.gov record NCT03537586 · retained source version 2026-11-04:db1a1899c7ca2974c6849e264eb0304e34233ede2c682b00f049cd40d093e675** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03537586) (`ctg-observation-nct03537586-2026-11-04-db1a1899c7ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03537586." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03537586-bivalirudin-v1 SHA-256: a0311d3687743ff8aa1c0ff8755fd472f77684ad5fb296e2200091852265c0ea.

---

<a id="clinicaltrials-gov-nct03588611-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT03588611

> PeptideScanner retained ClinicalTrials.gov record NCT03588611 at 2026-11-15T21:58:19.888Z. Its registry update date was 2021-08-09, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct03588611-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-08-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03588611-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03588611-bivalirudin-v1
- Content SHA-256: `38dfeecdc146609e8d2669616288c561a0e5730df7dc4f06c4e8aebe7eb455ec`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03588611 ([`ctg-observation-nct03588611-2021-08-09-647ce41e09f9`](#source-ctg-observation-nct03588611-2021-08-09-647ce41e09f9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03588611 at 2026-11-15T21:58:19.888Z. Its registry update date was 2021-08-09, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03588611-2021-08-09-647ce41e09f9`](#source-ctg-observation-nct03588611-2021-08-09-647ce41e09f9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03588611 at 2026-11-15T21:58:19.888Z. Its registry update date was 2021-08-09, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03588611-2021-08-09-647ce41e09f9`](#source-ctg-observation-nct03588611-2021-08-09-647ce41e09f9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03588611-2021-08-09-647ce41e09f9`](#source-ctg-observation-nct03588611-2021-08-09-647ce41e09f9))

### Sources

<a id="source-ctg-observation-nct03588611-2021-08-09-647ce41e09f9"></a>
- **ClinicalTrials.gov record NCT03588611 · retained source version 2021-08-09:647ce41e09f9c27ed719f227a06a7db9e14020e463cfb180a936928972bc33e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03588611) (`ctg-observation-nct03588611-2021-08-09-647ce41e09f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03588611." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03588611-bivalirudin-v1 SHA-256: 38dfeecdc146609e8d2669616288c561a0e5730df7dc4f06c4e8aebe7eb455ec.

---

<a id="clinicaltrials-gov-nct03664180-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT03664180

> PeptideScanner retained ClinicalTrials.gov record NCT03664180 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-05-03, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct03664180-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03664180-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03664180-bivalirudin-v1
- Content SHA-256: `4ef2fa82a4d3577db23c75ec6111cd6b6c91db2760309d2f2eee8305870dc003`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03664180 ([`ctg-observation-nct03664180-2023-05-03-ca89096c5863`](#source-ctg-observation-nct03664180-2023-05-03-ca89096c5863))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03664180 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-05-03, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03664180-2023-05-03-ca89096c5863`](#source-ctg-observation-nct03664180-2023-05-03-ca89096c5863))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03664180 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-05-03, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03664180-2023-05-03-ca89096c5863`](#source-ctg-observation-nct03664180-2023-05-03-ca89096c5863))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03664180-2023-05-03-ca89096c5863`](#source-ctg-observation-nct03664180-2023-05-03-ca89096c5863))

### Sources

<a id="source-ctg-observation-nct03664180-2023-05-03-ca89096c5863"></a>
- **ClinicalTrials.gov record NCT03664180 · retained source version 2023-05-03:ca89096c5863448c765545f456db3a9f0eae2d2b41abaff36b38207eccbfe0fd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03664180) (`ctg-observation-nct03664180-2023-05-03-ca89096c5863`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03664180." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03664180-bivalirudin-v1 SHA-256: 4ef2fa82a4d3577db23c75ec6111cd6b6c91db2760309d2f2eee8305870dc003.

---

<a id="clinicaltrials-gov-nct03822975-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT03822975

> PeptideScanner retained ClinicalTrials.gov record NCT03822975 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct03822975-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03822975-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03822975-bivalirudin-v1
- Content SHA-256: `470356d29ab9891df83fa96c6aff1c1644ff05e0969cc6d02af326c43056878e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03822975 ([`ctg-observation-nct03822975-2025-08-27-b4b86c39d16d`](#source-ctg-observation-nct03822975-2025-08-27-b4b86c39d16d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03822975 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03822975-2025-08-27-b4b86c39d16d`](#source-ctg-observation-nct03822975-2025-08-27-b4b86c39d16d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03822975 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct03822975-2025-08-27-b4b86c39d16d`](#source-ctg-observation-nct03822975-2025-08-27-b4b86c39d16d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03822975-2025-08-27-b4b86c39d16d`](#source-ctg-observation-nct03822975-2025-08-27-b4b86c39d16d))

### Sources

<a id="source-ctg-observation-nct03822975-2025-08-27-b4b86c39d16d"></a>
- **ClinicalTrials.gov record NCT03822975 · retained source version 2025-08-27:b4b86c39d16da013c71ad763c9e2bc2ce4e108e9fe33f710eaea18fb0a28b06d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03822975) (`ctg-observation-nct03822975-2025-08-27-b4b86c39d16d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03822975." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct03822975-bivalirudin-v1 SHA-256: 470356d29ab9891df83fa96c6aff1c1644ff05e0969cc6d02af326c43056878e.

---

<a id="clinicaltrials-gov-nct04278404-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT04278404

> PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct04278404-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04278404-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct04278404-bivalirudin-v1
- Content SHA-256: `aa7b87c4d299b2451ca40f2ecb09997383564ec9a462bd9bc322e272a41b5ce6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04278404 ([`ctg-observation-nct04278404-2026-08-21-a412c0daed44`](#source-ctg-observation-nct04278404-2026-08-21-a412c0daed44))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct04278404-2026-08-21-a412c0daed44`](#source-ctg-observation-nct04278404-2026-08-21-a412c0daed44))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct04278404-2026-08-21-a412c0daed44`](#source-ctg-observation-nct04278404-2026-08-21-a412c0daed44))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04278404-2026-08-21-a412c0daed44`](#source-ctg-observation-nct04278404-2026-08-21-a412c0daed44))

### Sources

<a id="source-ctg-observation-nct04278404-2026-08-21-a412c0daed44"></a>
- **ClinicalTrials.gov record NCT04278404 · retained source version 2026-08-21:a412c0daed4449b19a22cb6feb7a1be4e052a660ad6359bb46bfd0be53505981** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04278404) (`ctg-observation-nct04278404-2026-08-21-a412c0daed44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04278404." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct04278404-bivalirudin-v1 SHA-256: aa7b87c4d299b2451ca40f2ecb09997383564ec9a462bd9bc322e272a41b5ce6.

---

<a id="clinicaltrials-gov-nct05959252-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT05959252

> PeptideScanner retained ClinicalTrials.gov record NCT05959252 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct05959252-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05959252-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct05959252-bivalirudin-v1
- Content SHA-256: `1d35edd7e690154b650d581cb4067dbe30c147f2a5e37ee075e1cd2118b62466`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05959252 ([`ctg-observation-nct05959252-2026-05-08-73e4418eb01e`](#source-ctg-observation-nct05959252-2026-05-08-73e4418eb01e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05959252 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct05959252-2026-05-08-73e4418eb01e`](#source-ctg-observation-nct05959252-2026-05-08-73e4418eb01e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05959252 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct05959252-2026-05-08-73e4418eb01e`](#source-ctg-observation-nct05959252-2026-05-08-73e4418eb01e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05959252-2026-05-08-73e4418eb01e`](#source-ctg-observation-nct05959252-2026-05-08-73e4418eb01e))

### Sources

<a id="source-ctg-observation-nct05959252-2026-05-08-73e4418eb01e"></a>
- **ClinicalTrials.gov record NCT05959252 · retained source version 2026-05-08:73e4418eb01e6c6ec0147c1f758a4e123923c40f8e0eef2f7fe63f23d4c1a566** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05959252) (`ctg-observation-nct05959252-2026-05-08-73e4418eb01e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05959252." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct05959252-bivalirudin-v1 SHA-256: 1d35edd7e690154b650d581cb4067dbe30c147f2a5e37ee075e1cd2118b62466.

---

<a id="clinicaltrials-gov-nct05984537-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT05984537

> PeptideScanner retained ClinicalTrials.gov record NCT05984537 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-12, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct05984537-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05984537-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct05984537-bivalirudin-v1
- Content SHA-256: `f9a3b84bcfdeab5e4501f25e6cb75303a97bf87ea0ad3f95461c6124090161de`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05984537 ([`ctg-observation-nct05984537-2025-08-12-d670c7fed535`](#source-ctg-observation-nct05984537-2025-08-12-d670c7fed535))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05984537 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-12, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct05984537-2025-08-12-d670c7fed535`](#source-ctg-observation-nct05984537-2025-08-12-d670c7fed535))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05984537 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-08-12, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct05984537-2025-08-12-d670c7fed535`](#source-ctg-observation-nct05984537-2025-08-12-d670c7fed535))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05984537-2025-08-12-d670c7fed535`](#source-ctg-observation-nct05984537-2025-08-12-d670c7fed535))

### Sources

<a id="source-ctg-observation-nct05984537-2025-08-12-d670c7fed535"></a>
- **ClinicalTrials.gov record NCT05984537 · retained source version 2025-08-12:d670c7fed535d829e565e7fb70a31d4dd5b3762101b27da0464062ee855a9ea3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05984537) (`ctg-observation-nct05984537-2025-08-12-d670c7fed535`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05984537." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct05984537-bivalirudin-v1 SHA-256: f9a3b84bcfdeab5e4501f25e6cb75303a97bf87ea0ad3f95461c6124090161de.

---

<a id="clinicaltrials-gov-nct06080074-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT06080074

> PeptideScanner retained ClinicalTrials.gov record NCT06080074 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct06080074-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06080074-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct06080074-bivalirudin-v1
- Content SHA-256: `8162b84f76236ea3c0d3eba7768030b77f8e640f085df6dd30caa7b0b0d58122`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06080074 ([`ctg-observation-nct06080074-2026-08-10-c4926e645baf`](#source-ctg-observation-nct06080074-2026-08-10-c4926e645baf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06080074 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct06080074-2026-08-10-c4926e645baf`](#source-ctg-observation-nct06080074-2026-08-10-c4926e645baf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06080074 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct06080074-2026-08-10-c4926e645baf`](#source-ctg-observation-nct06080074-2026-08-10-c4926e645baf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06080074-2026-08-10-c4926e645baf`](#source-ctg-observation-nct06080074-2026-08-10-c4926e645baf))

### Sources

<a id="source-ctg-observation-nct06080074-2026-08-10-c4926e645baf"></a>
- **ClinicalTrials.gov record NCT06080074 · retained source version 2026-08-10:c4926e645baf9d7ec7b71a006dcd8c3dbb3029a67208918c2f4342ffc877b9f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06080074) (`ctg-observation-nct06080074-2026-08-10-c4926e645baf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06080074." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct06080074-bivalirudin-v1 SHA-256: 8162b84f76236ea3c0d3eba7768030b77f8e640f085df6dd30caa7b0b0d58122.

---

<a id="clinicaltrials-gov-nct06275555-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT06275555

> PeptideScanner retained ClinicalTrials.gov record NCT06275555 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct06275555-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06275555-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct06275555-bivalirudin-v1
- Content SHA-256: `44507b795f6826d00c97c54b2f12e86a524883329c4200594d8b3c4619f27983`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06275555 ([`ctg-observation-nct06275555-2026-04-06-27333d8c41b4`](#source-ctg-observation-nct06275555-2026-04-06-27333d8c41b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06275555 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct06275555-2026-04-06-27333d8c41b4`](#source-ctg-observation-nct06275555-2026-04-06-27333d8c41b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06275555 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct06275555-2026-04-06-27333d8c41b4`](#source-ctg-observation-nct06275555-2026-04-06-27333d8c41b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06275555-2026-04-06-27333d8c41b4`](#source-ctg-observation-nct06275555-2026-04-06-27333d8c41b4))

### Sources

<a id="source-ctg-observation-nct06275555-2026-04-06-27333d8c41b4"></a>
- **ClinicalTrials.gov record NCT06275555 · retained source version 2026-04-06:27333d8c41b4a557ca3cdd6e1725c54812c1e215728bad2fd32a9ba9d5a3c262** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06275555) (`ctg-observation-nct06275555-2026-04-06-27333d8c41b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06275555." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct06275555-bivalirudin-v1 SHA-256: 44507b795f6826d00c97c54b2f12e86a524883329c4200594d8b3c4619f27983.

---

<a id="clinicaltrials-gov-nct06861374-bivalirudin-v1"></a>

## ClinicalTrials.gov record NCT06861374

> PeptideScanner retained ClinicalTrials.gov record NCT06861374 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-03-06, and PeptideScanner's reviewed identity mapping was bivalirudin.

- Evidence object: `story:clinicaltrials-gov-nct06861374-bivalirudin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06861374-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct06861374-bivalirudin-v1
- Content SHA-256: `a7e9379ad786af74278f085bf50d93f151bd9d939601f7c734c0416b133c26cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06861374 ([`ctg-observation-nct06861374-2025-03-06-674116a3eb41`](#source-ctg-observation-nct06861374-2025-03-06-674116a3eb41))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06861374 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-03-06, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct06861374-2025-03-06-674116a3eb41`](#source-ctg-observation-nct06861374-2025-03-06-674116a3eb41))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06861374 at 2026-11-15T21:58:19.888Z. Its registry update date was 2025-03-06, and PeptideScanner's reviewed identity mapping was bivalirudin. ([`ctg-observation-nct06861374-2025-03-06-674116a3eb41`](#source-ctg-observation-nct06861374-2025-03-06-674116a3eb41))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06861374-2025-03-06-674116a3eb41`](#source-ctg-observation-nct06861374-2025-03-06-674116a3eb41))

### Sources

<a id="source-ctg-observation-nct06861374-2025-03-06-674116a3eb41"></a>
- **ClinicalTrials.gov record NCT06861374 · retained source version 2025-03-06:674116a3eb412b555a966110c9b79ec8584552f6205176ffc0fe7a76a6d18f5e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06861374) (`ctg-observation-nct06861374-2025-03-06-674116a3eb41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06861374." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#clinicaltrials-gov-nct06861374-bivalirudin-v1 SHA-256: a7e9379ad786af74278f085bf50d93f151bd9d939601f7c734c0416b133c26cd.

---

<a id="fda-drugs-anda090189-v1"></a>

## Drugs@FDA application ANDA090189

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090189 with status AP dated 2016-10-28, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090189:v1`
- Evidence domain: Regulatory
- Date in source: 2016-10-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090189/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda090189-v1
- Content SHA-256: `8abf101bb9f5c525289003805879df10a1dd8696a7bef70a0f84ad82936024ae`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090189 ([`fda-drugs-anda090189-2016-10-28-d6fa859c8592`](#source-fda-drugs-anda090189-2016-10-28-d6fa859c8592))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090189 with status AP dated 2016-10-28, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda090189-2016-10-28-d6fa859c8592`](#source-fda-drugs-anda090189-2016-10-28-d6fa859c8592))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090189 with status AP dated 2016-10-28, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda090189-2016-10-28-d6fa859c8592`](#source-fda-drugs-anda090189-2016-10-28-d6fa859c8592))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090189-2016-10-28-d6fa859c8592`](#source-fda-drugs-anda090189-2016-10-28-d6fa859c8592))

### Sources

<a id="source-fda-drugs-anda090189-2016-10-28-d6fa859c8592"></a>
- **Drugs@FDA application ANDA090189 · original submission status AP · 2016-10-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090189%22&limit=1) (`fda-drugs-anda090189-2016-10-28-d6fa859c8592`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090189." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda090189-v1 SHA-256: 8abf101bb9f5c525289003805879df10a1dd8696a7bef70a0f84ad82936024ae.

---

<a id="fda-drugs-anda090811-v1"></a>

## Drugs@FDA application ANDA090811

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090811 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090811:v1`
- Evidence domain: Regulatory
- Date in source: 2015-07-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090811/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda090811-v1
- Content SHA-256: `3d881da7a2980ca32c073559c91bd5601ea2e3e9fea1b5e3ca2e8bb92d8b3501`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090811 ([`fda-drugs-anda090811-2015-07-14-e9517db80cc5`](#source-fda-drugs-anda090811-2015-07-14-e9517db80cc5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090811 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda090811-2015-07-14-e9517db80cc5`](#source-fda-drugs-anda090811-2015-07-14-e9517db80cc5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090811 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda090811-2015-07-14-e9517db80cc5`](#source-fda-drugs-anda090811-2015-07-14-e9517db80cc5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090811-2015-07-14-e9517db80cc5`](#source-fda-drugs-anda090811-2015-07-14-e9517db80cc5))

### Sources

<a id="source-fda-drugs-anda090811-2015-07-14-e9517db80cc5"></a>
- **Drugs@FDA application ANDA090811 · original submission status AP · 2015-07-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090811%22&limit=1) (`fda-drugs-anda090811-2015-07-14-e9517db80cc5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090811." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda090811-v1 SHA-256: 3d881da7a2980ca32c073559c91bd5601ea2e3e9fea1b5e3ca2e8bb92d8b3501.

---

<a id="fda-drugs-anda090816-v1"></a>

## Drugs@FDA application ANDA090816

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090816 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090816:v1`
- Evidence domain: Regulatory
- Date in source: 2015-07-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090816/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda090816-v1
- Content SHA-256: `b380afd644af85e86b67bab66d41c10a934b8f18262d1391a84c90ff3947c7cb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090816 ([`fda-drugs-anda090816-2015-07-14-996f34e3eecc`](#source-fda-drugs-anda090816-2015-07-14-996f34e3eecc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090816 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda090816-2015-07-14-996f34e3eecc`](#source-fda-drugs-anda090816-2015-07-14-996f34e3eecc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090816 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda090816-2015-07-14-996f34e3eecc`](#source-fda-drugs-anda090816-2015-07-14-996f34e3eecc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090816-2015-07-14-996f34e3eecc`](#source-fda-drugs-anda090816-2015-07-14-996f34e3eecc))

### Sources

<a id="source-fda-drugs-anda090816-2015-07-14-996f34e3eecc"></a>
- **Drugs@FDA application ANDA090816 · original submission status AP · 2015-07-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090816%22&limit=1) (`fda-drugs-anda090816-2015-07-14-996f34e3eecc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090816." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda090816-v1 SHA-256: b380afd644af85e86b67bab66d41c10a934b8f18262d1391a84c90ff3947c7cb.

---

<a id="fda-drugs-anda091602-v1"></a>

## Drugs@FDA application ANDA091602

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091602 with status AP dated 2018-07-16, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091602:v1`
- Evidence domain: Regulatory
- Date in source: 2018-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091602/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda091602-v1
- Content SHA-256: `9f759403954a74ee3f5cc8bb2f511f3282033817b52d8a95caab56d4a5c8f81a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091602 ([`fda-drugs-anda091602-2018-07-16-01dc740fdd8e`](#source-fda-drugs-anda091602-2018-07-16-01dc740fdd8e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091602 with status AP dated 2018-07-16, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda091602-2018-07-16-01dc740fdd8e`](#source-fda-drugs-anda091602-2018-07-16-01dc740fdd8e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091602 with status AP dated 2018-07-16, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda091602-2018-07-16-01dc740fdd8e`](#source-fda-drugs-anda091602-2018-07-16-01dc740fdd8e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091602-2018-07-16-01dc740fdd8e`](#source-fda-drugs-anda091602-2018-07-16-01dc740fdd8e))

### Sources

<a id="source-fda-drugs-anda091602-2018-07-16-01dc740fdd8e"></a>
- **Drugs@FDA application ANDA091602 · original submission status AP · 2018-07-16 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091602%22&limit=1) (`fda-drugs-anda091602-2018-07-16-01dc740fdd8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091602." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda091602-v1 SHA-256: 9f759403954a74ee3f5cc8bb2f511f3282033817b52d8a95caab56d4a5c8f81a.

---

<a id="fda-drugs-anda201577-v1"></a>

## Drugs@FDA application ANDA201577

> The official Drugs@FDA dataset lists original submission 1 for ANDA 201577 with status AP dated 2017-05-26, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda201577:v1`
- Evidence domain: Regulatory
- Date in source: 2017-05-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda201577/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda201577-v1
- Content SHA-256: `874843487aa8ce511aec43263e072a11ca432e6327213ada26d77b1874c22d99`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA201577 ([`fda-drugs-anda201577-2017-05-26-e6231fbda617`](#source-fda-drugs-anda201577-2017-05-26-e6231fbda617))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 201577 with status AP dated 2017-05-26, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda201577-2017-05-26-e6231fbda617`](#source-fda-drugs-anda201577-2017-05-26-e6231fbda617))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 201577 with status AP dated 2017-05-26, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda201577-2017-05-26-e6231fbda617`](#source-fda-drugs-anda201577-2017-05-26-e6231fbda617))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda201577-2017-05-26-e6231fbda617`](#source-fda-drugs-anda201577-2017-05-26-e6231fbda617))

### Sources

<a id="source-fda-drugs-anda201577-2017-05-26-e6231fbda617"></a>
- **Drugs@FDA application ANDA201577 · original submission status AP · 2017-05-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA201577%22&limit=1) (`fda-drugs-anda201577-2017-05-26-e6231fbda617`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA201577." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda201577-v1 SHA-256: 874843487aa8ce511aec43263e072a11ca432e6327213ada26d77b1874c22d99.

---

<a id="fda-drugs-anda202471-v1"></a>

## Drugs@FDA application ANDA202471

> The official Drugs@FDA dataset lists original submission 1 for ANDA 202471 with status AP dated 2018-06-01, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda202471:v1`
- Evidence domain: Regulatory
- Date in source: 2018-06-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda202471/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda202471-v1
- Content SHA-256: `4743c8aa4b97ef488eb336b36d73e2ca232c1e93f9e4422d11c9ac5c6b255271`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA202471 ([`fda-drugs-anda202471-2018-06-01-449b503633a0`](#source-fda-drugs-anda202471-2018-06-01-449b503633a0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 202471 with status AP dated 2018-06-01, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda202471-2018-06-01-449b503633a0`](#source-fda-drugs-anda202471-2018-06-01-449b503633a0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 202471 with status AP dated 2018-06-01, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda202471-2018-06-01-449b503633a0`](#source-fda-drugs-anda202471-2018-06-01-449b503633a0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda202471-2018-06-01-449b503633a0`](#source-fda-drugs-anda202471-2018-06-01-449b503633a0))

### Sources

<a id="source-fda-drugs-anda202471-2018-06-01-449b503633a0"></a>
- **Drugs@FDA application ANDA202471 · original submission status AP · 2018-06-01 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA202471%22&limit=1) (`fda-drugs-anda202471-2018-06-01-449b503633a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA202471." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda202471-v1 SHA-256: 4743c8aa4b97ef488eb336b36d73e2ca232c1e93f9e4422d11c9ac5c6b255271.

---

<a id="fda-drugs-anda204876-v1"></a>

## Drugs@FDA application ANDA204876

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204876 with status AP dated 2017-07-06, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204876:v1`
- Evidence domain: Regulatory
- Date in source: 2017-07-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204876/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda204876-v1
- Content SHA-256: `da6a889a1ea3de6ec7cf9c8169e0d2bb9217d8f8fb032e9d1ad6882f15ed86ca`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204876 ([`fda-drugs-anda204876-2017-07-06-56edad7b4ae6`](#source-fda-drugs-anda204876-2017-07-06-56edad7b4ae6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204876 with status AP dated 2017-07-06, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda204876-2017-07-06-56edad7b4ae6`](#source-fda-drugs-anda204876-2017-07-06-56edad7b4ae6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204876 with status AP dated 2017-07-06, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda204876-2017-07-06-56edad7b4ae6`](#source-fda-drugs-anda204876-2017-07-06-56edad7b4ae6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204876-2017-07-06-56edad7b4ae6`](#source-fda-drugs-anda204876-2017-07-06-56edad7b4ae6))

### Sources

<a id="source-fda-drugs-anda204876-2017-07-06-56edad7b4ae6"></a>
- **Drugs@FDA application ANDA204876 · original submission status AP · 2017-07-06 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204876%22&limit=1) (`fda-drugs-anda204876-2017-07-06-56edad7b4ae6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204876." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda204876-v1 SHA-256: da6a889a1ea3de6ec7cf9c8169e0d2bb9217d8f8fb032e9d1ad6882f15ed86ca.

---

<a id="fda-drugs-anda205962-v1"></a>

## Drugs@FDA application ANDA205962

> The official Drugs@FDA dataset lists original submission 1 for ANDA 205962 with status AP dated 2018-07-27, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda205962:v1`
- Evidence domain: Regulatory
- Date in source: 2018-07-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda205962/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda205962-v1
- Content SHA-256: `fe77d595141c6b10fb91091ad5b28a7fff9948b4cf2173a3f835d5e8c0c0161a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA205962 ([`fda-drugs-anda205962-2018-07-27-295a80ed223c`](#source-fda-drugs-anda205962-2018-07-27-295a80ed223c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 205962 with status AP dated 2018-07-27, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda205962-2018-07-27-295a80ed223c`](#source-fda-drugs-anda205962-2018-07-27-295a80ed223c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 205962 with status AP dated 2018-07-27, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda205962-2018-07-27-295a80ed223c`](#source-fda-drugs-anda205962-2018-07-27-295a80ed223c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda205962-2018-07-27-295a80ed223c`](#source-fda-drugs-anda205962-2018-07-27-295a80ed223c))

### Sources

<a id="source-fda-drugs-anda205962-2018-07-27-295a80ed223c"></a>
- **Drugs@FDA application ANDA205962 · original submission status AP · 2018-07-27 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA205962%22&limit=1) (`fda-drugs-anda205962-2018-07-27-295a80ed223c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA205962." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda205962-v1 SHA-256: fe77d595141c6b10fb91091ad5b28a7fff9948b4cf2173a3f835d5e8c0c0161a.

---

<a id="fda-drugs-anda206551-v1"></a>

## Drugs@FDA application ANDA206551

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206551 with status AP dated 2017-11-22, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206551:v1`
- Evidence domain: Regulatory
- Date in source: 2017-11-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206551/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda206551-v1
- Content SHA-256: `e206ef784adfd7eb6b5bf369bd46338148996699f855e12574a2a7500e4a04cd`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206551 ([`fda-drugs-anda206551-2017-11-22-f06d45b56472`](#source-fda-drugs-anda206551-2017-11-22-f06d45b56472))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206551 with status AP dated 2017-11-22, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda206551-2017-11-22-f06d45b56472`](#source-fda-drugs-anda206551-2017-11-22-f06d45b56472))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206551 with status AP dated 2017-11-22, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda206551-2017-11-22-f06d45b56472`](#source-fda-drugs-anda206551-2017-11-22-f06d45b56472))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206551-2017-11-22-f06d45b56472`](#source-fda-drugs-anda206551-2017-11-22-f06d45b56472))

### Sources

<a id="source-fda-drugs-anda206551-2017-11-22-f06d45b56472"></a>
- **Drugs@FDA application ANDA206551 · original submission status AP · 2017-11-22 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206551%22&limit=1) (`fda-drugs-anda206551-2017-11-22-f06d45b56472`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206551." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda206551-v1 SHA-256: e206ef784adfd7eb6b5bf369bd46338148996699f855e12574a2a7500e4a04cd.

---

<a id="fda-drugs-anda210031-v1"></a>

## Drugs@FDA application ANDA210031

> The official Drugs@FDA dataset lists original submission 1 for ANDA 210031 with status AP dated 2019-10-23, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda210031:v1`
- Evidence domain: Regulatory
- Date in source: 2019-10-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda210031/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda210031-v1
- Content SHA-256: `585d077d64df0c780518aa291f9780c52377d901a9259f5b4aaf0520b5ec2f8d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA210031 ([`fda-drugs-anda210031-2019-10-23-e4c75b87a349`](#source-fda-drugs-anda210031-2019-10-23-e4c75b87a349))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 210031 with status AP dated 2019-10-23, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda210031-2019-10-23-e4c75b87a349`](#source-fda-drugs-anda210031-2019-10-23-e4c75b87a349))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 210031 with status AP dated 2019-10-23, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda210031-2019-10-23-e4c75b87a349`](#source-fda-drugs-anda210031-2019-10-23-e4c75b87a349))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda210031-2019-10-23-e4c75b87a349`](#source-fda-drugs-anda210031-2019-10-23-e4c75b87a349))

### Sources

<a id="source-fda-drugs-anda210031-2019-10-23-e4c75b87a349"></a>
- **Drugs@FDA application ANDA210031 · original submission status AP · 2019-10-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA210031%22&limit=1) (`fda-drugs-anda210031-2019-10-23-e4c75b87a349`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA210031." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda210031-v1 SHA-256: 585d077d64df0c780518aa291f9780c52377d901a9259f5b4aaf0520b5ec2f8d.

---

<a id="fda-drugs-anda213078-v1"></a>

## Drugs@FDA application ANDA213078

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213078 with status AP dated 2021-05-28, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213078:v1`
- Evidence domain: Regulatory
- Date in source: 2021-05-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213078/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda213078-v1
- Content SHA-256: `788daddc6e2de0ce1c33a94cdeb24a483c14d5ae36b998a5bc165a5d4f3f634a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213078 ([`fda-drugs-anda213078-2021-05-28-05d299414ea1`](#source-fda-drugs-anda213078-2021-05-28-05d299414ea1))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213078 with status AP dated 2021-05-28, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda213078-2021-05-28-05d299414ea1`](#source-fda-drugs-anda213078-2021-05-28-05d299414ea1))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213078 with status AP dated 2021-05-28, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-anda213078-2021-05-28-05d299414ea1`](#source-fda-drugs-anda213078-2021-05-28-05d299414ea1))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213078-2021-05-28-05d299414ea1`](#source-fda-drugs-anda213078-2021-05-28-05d299414ea1))

### Sources

<a id="source-fda-drugs-anda213078-2021-05-28-05d299414ea1"></a>
- **Drugs@FDA application ANDA213078 · original submission status AP · 2021-05-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213078%22&limit=1) (`fda-drugs-anda213078-2021-05-28-05d299414ea1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213078." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-anda213078-v1 SHA-256: 788daddc6e2de0ce1c33a94cdeb24a483c14d5ae36b998a5bc165a5d4f3f634a.

---

<a id="fda-drugs-nda020873-v1"></a>

## Drugs@FDA application NDA020873

> The official Drugs@FDA dataset lists original submission 1 for NDA 020873 with status AP dated 2000-12-15, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020873:v1`
- Evidence domain: Regulatory
- Date in source: 2000-12-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020873/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-nda020873-v1
- Content SHA-256: `552d763b52338f89eda18c3349a30147e6f7d6bc7eeebc28018c4807c15b6ce8`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020873 ([`fda-drugs-nda020873-2000-12-15-48aea8c532fb`](#source-fda-drugs-nda020873-2000-12-15-48aea8c532fb))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020873 with status AP dated 2000-12-15, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-nda020873-2000-12-15-48aea8c532fb`](#source-fda-drugs-nda020873-2000-12-15-48aea8c532fb))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020873 with status AP dated 2000-12-15, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-nda020873-2000-12-15-48aea8c532fb`](#source-fda-drugs-nda020873-2000-12-15-48aea8c532fb))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020873-2000-12-15-48aea8c532fb`](#source-fda-drugs-nda020873-2000-12-15-48aea8c532fb))

### Sources

<a id="source-fda-drugs-nda020873-2000-12-15-48aea8c532fb"></a>
- **Drugs@FDA application NDA020873 · original submission status AP · 2000-12-15 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020873%22&limit=1) (`fda-drugs-nda020873-2000-12-15-48aea8c532fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020873." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-nda020873-v1 SHA-256: 552d763b52338f89eda18c3349a30147e6f7d6bc7eeebc28018c4807c15b6ce8.

---

<a id="fda-drugs-nda208374-v1"></a>

## Drugs@FDA application NDA208374

> The official Drugs@FDA dataset lists original submission 1 for NDA 208374 with status AP dated 2017-12-21, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208374:v1`
- Evidence domain: Regulatory
- Date in source: 2017-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208374/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-nda208374-v1
- Content SHA-256: `30a0b005f5c40f551f79f87cac2b2285279f06e6cd94d58d9ccdc65bdc256f0c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208374 ([`fda-drugs-nda208374-2017-12-21-73cc28942813`](#source-fda-drugs-nda208374-2017-12-21-73cc28942813))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208374 with status AP dated 2017-12-21, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-nda208374-2017-12-21-73cc28942813`](#source-fda-drugs-nda208374-2017-12-21-73cc28942813))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208374 with status AP dated 2017-12-21, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-nda208374-2017-12-21-73cc28942813`](#source-fda-drugs-nda208374-2017-12-21-73cc28942813))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208374-2017-12-21-73cc28942813`](#source-fda-drugs-nda208374-2017-12-21-73cc28942813))

### Sources

<a id="source-fda-drugs-nda208374-2017-12-21-73cc28942813"></a>
- **Drugs@FDA application NDA208374 · original submission status AP · 2017-12-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208374%22&limit=1) (`fda-drugs-nda208374-2017-12-21-73cc28942813`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208374." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-nda208374-v1 SHA-256: 30a0b005f5c40f551f79f87cac2b2285279f06e6cd94d58d9ccdc65bdc256f0c.

---

<a id="fda-drugs-nda211215-v1"></a>

## Drugs@FDA application NDA211215

> The official Drugs@FDA dataset lists original submission 1 for NDA 211215 with status AP dated 2019-07-25, and names bivalirudin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda211215:v1`
- Evidence domain: Regulatory
- Date in source: 2019-07-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda211215/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-nda211215-v1
- Content SHA-256: `c5de2ace3e30a2220d4e3f23edf664f7b3fecfbfafba81ccff4767f84b31060a`

### Claims and source pins

#### Headline

Drugs@FDA application NDA211215 ([`fda-drugs-nda211215-2019-07-25-25b00f3e0f09`](#source-fda-drugs-nda211215-2019-07-25-25b00f3e0f09))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 211215 with status AP dated 2019-07-25, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-nda211215-2019-07-25-25b00f3e0f09`](#source-fda-drugs-nda211215-2019-07-25-25b00f3e0f09))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 211215 with status AP dated 2019-07-25, and names bivalirudin among the application record's active ingredients. ([`fda-drugs-nda211215-2019-07-25-25b00f3e0f09`](#source-fda-drugs-nda211215-2019-07-25-25b00f3e0f09))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda211215-2019-07-25-25b00f3e0f09`](#source-fda-drugs-nda211215-2019-07-25-25b00f3e0f09))

### Sources

<a id="source-fda-drugs-nda211215-2019-07-25-25b00f3e0f09"></a>
- **Drugs@FDA application NDA211215 · original submission status AP · 2019-07-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA211215%22&limit=1) (`fda-drugs-nda211215-2019-07-25-25b00f3e0f09`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA211215." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#fda-drugs-nda211215-v1 SHA-256: c5de2ace3e30a2220d4e3f23edf664f7b3fecfbfafba81ccff4767f84b31060a.

---

<a id="federal-register-2010-31583-v1"></a>

## Federal Register notice 2010-31583

> The Federal Register published notice 2010-31583, attributed to FDA and its parent HHS department, on 2010-12-16. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

- Evidence object: `story:federal-register-2010-31583:v1`
- Evidence domain: Regulatory
- Date in source: 2010-12-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2010-31583/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-2010-31583-v1
- Content SHA-256: `4cf436d156a9683f9665473207f25856d093476c90ba24b842bb720eecb3f741`

### Claims and source pins

#### Headline

Federal Register notice 2010-31583 ([`federal-register-2010-31583-d41091050d1d`](#source-federal-register-2010-31583-d41091050d1d))

#### Summary

The Federal Register published notice 2010-31583, attributed to FDA and its parent HHS department, on 2010-12-16. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-2010-31583-d41091050d1d`](#source-federal-register-2010-31583-d41091050d1d))

#### Paragraph 1

The Federal Register published notice 2010-31583, attributed to FDA and its parent HHS department, on 2010-12-16. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-2010-31583-d41091050d1d`](#source-federal-register-2010-31583-d41091050d1d))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2010-31583-d41091050d1d`](#source-federal-register-2010-31583-d41091050d1d))

### Sources

<a id="source-federal-register-2010-31583-d41091050d1d"></a>
- **Federal Register notice 2010-31583 · published 2010-12-16 · Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2010-12-16/pdf/2010-31583.pdf) (`federal-register-2010-31583-d41091050d1d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2010-31583." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-2010-31583-v1 SHA-256: 4cf436d156a9683f9665473207f25856d093476c90ba24b842bb720eecb3f741.

---

<a id="federal-register-2023-19013-v1"></a>

## Federal Register notice 2023-19013

> The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

- Evidence object: `story:federal-register-2023-19013:v1`
- Evidence domain: Regulatory
- Date in source: 2023-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-19013/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-2023-19013-v1
- Content SHA-256: `1a8e62420bc8510bd42bd758aec5fe1338e3404347757acd43256d1a466778d2`

### Claims and source pins

#### Headline

Federal Register notice 2023-19013 ([`federal-register-2023-19013-ce520610e193`](#source-federal-register-2023-19013-ce520610e193))

#### Summary

The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-2023-19013-ce520610e193`](#source-federal-register-2023-19013-ce520610e193))

#### Paragraph 1

The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-2023-19013-ce520610e193`](#source-federal-register-2023-19013-ce520610e193))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-19013-ce520610e193`](#source-federal-register-2023-19013-ce520610e193))

### Sources

<a id="source-federal-register-2023-19013-ce520610e193"></a>
- **Federal Register notice 2023-19013 · published 2023-09-05 · Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-09-05/pdf/2023-19013.pdf) (`federal-register-2023-19013-ce520610e193`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-19013." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-2023-19013-v1 SHA-256: 1a8e62420bc8510bd42bd758aec5fe1338e3404347757acd43256d1a466778d2.

---

<a id="federal-register-2025-18453-v1"></a>

## Federal Register notice 2025-18453

> The Federal Register published notice 2025-18453, attributed to FDA and its parent HHS department, on 2025-09-24. Its official title is “Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

- Evidence object: `story:federal-register-2025-18453:v1`
- Evidence domain: Regulatory
- Date in source: 2025-09-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-18453/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-2025-18453-v1
- Content SHA-256: `53c51aa7dd472e934ace424512d5a082a3eeb541ee741c63a7af743a911c7948`

### Claims and source pins

#### Headline

Federal Register notice 2025-18453 ([`federal-register-2025-18453-d07282490caf`](#source-federal-register-2025-18453-d07282490caf))

#### Summary

The Federal Register published notice 2025-18453, attributed to FDA and its parent HHS department, on 2025-09-24. Its official title is “Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-2025-18453-d07282490caf`](#source-federal-register-2025-18453-d07282490caf))

#### Paragraph 1

The Federal Register published notice 2025-18453, attributed to FDA and its parent HHS department, on 2025-09-24. Its official title is “Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-2025-18453-d07282490caf`](#source-federal-register-2025-18453-d07282490caf))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-18453-d07282490caf`](#source-federal-register-2025-18453-d07282490caf))

### Sources

<a id="source-federal-register-2025-18453-d07282490caf"></a>
- **Federal Register notice 2025-18453 · published 2025-09-24 · Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-09-24/pdf/2025-18453.pdf) (`federal-register-2025-18453-d07282490caf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-18453." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-2025-18453-v1 SHA-256: 53c51aa7dd472e934ace424512d5a082a3eeb541ee741c63a7af743a911c7948.

---

<a id="federal-register-98-25360-v1"></a>

## Federal Register notice 98-25360

> The Federal Register published notice 98-25360, attributed to FDA and its parent HHS department, on 1998-09-23. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

- Evidence object: `story:federal-register-98-25360:v1`
- Evidence domain: Regulatory
- Date in source: 1998-09-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-98-25360/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-98-25360-v1
- Content SHA-256: `d20abb73b05478c0d941d9c0d75dc7ea0fe26f76f61ff8f31018acb38a22515d`

### Claims and source pins

#### Headline

Federal Register notice 98-25360 ([`federal-register-98-25360-b57b35ac7830`](#source-federal-register-98-25360-b57b35ac7830))

#### Summary

The Federal Register published notice 98-25360, attributed to FDA and its parent HHS department, on 1998-09-23. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-98-25360-b57b35ac7830`](#source-federal-register-98-25360-b57b35ac7830))

#### Paragraph 1

The Federal Register published notice 98-25360, attributed to FDA and its parent HHS department, on 1998-09-23. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin. ([`federal-register-98-25360-b57b35ac7830`](#source-federal-register-98-25360-b57b35ac7830))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-98-25360-b57b35ac7830`](#source-federal-register-98-25360-b57b35ac7830))

### Sources

<a id="source-federal-register-98-25360-b57b35ac7830"></a>
- **Federal Register notice 98-25360 · published 1998-09-23 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1998-09-23/pdf/98-25360.pdf) (`federal-register-98-25360-b57b35ac7830`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 98-25360." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#federal-register-98-25360-v1 SHA-256: d20abb73b05478c0d941d9c0d75dc7ea0fe26f76f61ff8f31018acb38a22515d.

---

<a id="pubmed-pmid-29461391-bivalirudin-v1"></a>

## Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.

> PubMed lists PMID 29461391 in Anesthesia and analgesia as Journal Article, Review, with publication-date metadata of 2019-01 (month precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29461391-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29461391-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-29461391-bivalirudin-v1
- Content SHA-256: `d46264e18f084e441e9016e087a590a0cdb3676e45d04d45fa8f2ff5d42d3bd9`

### Claims and source pins

#### Headline

Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. ([`pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05`](#source-pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05))

#### Summary

PubMed lists PMID 29461391 in Anesthesia and analgesia as Journal Article, Review, with publication-date metadata of 2019-01 (month precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05`](#source-pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05))

#### Paragraph 1

PubMed lists PMID 29461391 in Anesthesia and analgesia as Journal Article, Review, with publication-date metadata of 2019-01 (month precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05`](#source-pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05`](#source-pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05))

### Sources

<a id="source-pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05"></a>
- **Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. · retained source version 1:2026-11-09:current:116b3b720c050be5aeddd67d0192d5cd531b8b93524edc932a467a66291d28d7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29461391/) (`pubmed-observation-pmid-29461391-2026-11-09-116b3b720c05`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-29461391-bivalirudin-v1 SHA-256: d46264e18f084e441e9016e087a590a0cdb3676e45d04d45fa8f2ff5d42d3bd9.

---

<a id="pubmed-pmid-31241442-bivalirudin-v1"></a>

## Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials.

> PubMed lists PMID 31241442 in Cardiovascular & hematological disorders drug targets as Journal Article, Systematic Review, with publication-date metadata of 2020 (year precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31241442-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31241442-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31241442-bivalirudin-v1
- Content SHA-256: `953207a9d8b972f0939bd452419358e540a16b0ba20a28b60d51593efd7b08e3`

### Claims and source pins

#### Headline

Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. ([`pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363`](#source-pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363))

#### Summary

PubMed lists PMID 31241442 in Cardiovascular & hematological disorders drug targets as Journal Article, Systematic Review, with publication-date metadata of 2020 (year precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363`](#source-pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363))

#### Paragraph 1

PubMed lists PMID 31241442 in Cardiovascular & hematological disorders drug targets as Journal Article, Systematic Review, with publication-date metadata of 2020 (year precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363`](#source-pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363`](#source-pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363))

### Sources

<a id="source-pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363"></a>
- **Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. · retained source version 1:2021-03-18:current:7a7bc90983639b30e5797c61c19f9f7e6450af923847c1bec3dfa491edfc565a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31241442/) (`pubmed-observation-pmid-31241442-2021-03-18-7a7bc9098363`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31241442-bivalirudin-v1 SHA-256: 953207a9d8b972f0939bd452419358e540a16b0ba20a28b60d51593efd7b08e3.

---

<a id="pubmed-pmid-31396727-bivalirudin-v1"></a>

## Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin.

> PubMed lists PMID 31396727 in Pharmaceutical research as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2019-08-08 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31396727-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-02-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31396727-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31396727-bivalirudin-v1
- Content SHA-256: `92a997864d72e7ecfd94dca05fc6a7c76114d0ee81be2d5d42716d76aa5b3839`

### Claims and source pins

#### Headline

Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin. ([`pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5`](#source-pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5))

#### Summary

PubMed lists PMID 31396727 in Pharmaceutical research as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2019-08-08 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5`](#source-pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5))

#### Paragraph 1

PubMed lists PMID 31396727 in Pharmaceutical research as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2019-08-08 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5`](#source-pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5`](#source-pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5))

### Sources

<a id="source-pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5"></a>
- **Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin. · retained source version 1:2020-02-25:current:85a7aceae8e5d2b120283986585d68371549eaee2efd517c923461fb8443e79b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31396727/) (`pubmed-observation-pmid-31396727-2020-02-25-85a7aceae8e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31396727-bivalirudin-v1 SHA-256: 92a997864d72e7ecfd94dca05fc6a7c76114d0ee81be2d5d42716d76aa5b3839.

---

<a id="pubmed-pmid-31521492-bivalirudin-v1"></a>

## Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice.

> PubMed lists PMID 31521492 in Journal of cardiothoracic and vascular anesthesia as Journal Article, Review, with publication-date metadata of 2019-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31521492-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-05-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31521492-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31521492-bivalirudin-v1
- Content SHA-256: `c6440263660394c0346f6470cc4a2c403c6a19262ccd7c6087345205768ab273`

### Claims and source pins

#### Headline

Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice. ([`pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea`](#source-pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea))

#### Summary

PubMed lists PMID 31521492 in Journal of cardiothoracic and vascular anesthesia as Journal Article, Review, with publication-date metadata of 2019-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea`](#source-pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea))

#### Paragraph 1

PubMed lists PMID 31521492 in Journal of cardiothoracic and vascular anesthesia as Journal Article, Review, with publication-date metadata of 2019-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea`](#source-pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea`](#source-pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea))

### Sources

<a id="source-pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea"></a>
- **Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice. · retained source version 1:2022-05-31:current:7d4f755848ea6f1cada57144d0189ad434c81cb224b859ceeeb54d5b9a0f9a46** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31521492/) (`pubmed-observation-pmid-31521492-2022-05-31-7d4f755848ea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31521492-bivalirudin-v1 SHA-256: c6440263660394c0346f6470cc4a2c403c6a19262ccd7c6087345205768ab273.

---

<a id="pubmed-pmid-31820428-bivalirudin-v1"></a>

## Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology.

> PubMed lists PMID 31820428 in Thrombosis and haemostasis as Comparative Study, Letter, Systematic Review, with publication-date metadata of 2019-12-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31820428-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31820428-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31820428-bivalirudin-v1
- Content SHA-256: `71ac683f39d196802e0919fc96691f6af7d3e471c8ca05727ab96f7d8d05b8e6`

### Claims and source pins

#### Headline

Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. ([`pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9`](#source-pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9))

#### Summary

PubMed lists PMID 31820428 in Thrombosis and haemostasis as Comparative Study, Letter, Systematic Review, with publication-date metadata of 2019-12-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9`](#source-pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9))

#### Paragraph 1

PubMed lists PMID 31820428 in Thrombosis and haemostasis as Comparative Study, Letter, Systematic Review, with publication-date metadata of 2019-12-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9`](#source-pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9`](#source-pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9))

### Sources

<a id="source-pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9"></a>
- **Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. · retained source version 1:2024-08-24:current:df6d355e29a9bb9e1a2790b090764e2bb011cf65c2d398dc323360305a2bfe51** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31820428/) (`pubmed-observation-pmid-31820428-2024-08-24-df6d355e29a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-31820428-bivalirudin-v1 SHA-256: 71ac683f39d196802e0919fc96691f6af7d3e471c8ca05727ab96f7d8d05b8e6.

---

<a id="pubmed-pmid-32091668-bivalirudin-v1"></a>

## Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.

> PubMed lists PMID 32091668 in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32091668-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-08-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32091668-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-32091668-bivalirudin-v1
- Content SHA-256: `4ef05b510eb06886df4ef446d768d82e6c03752d19398c7bec9d7f80992de5a6`

### Claims and source pins

#### Headline

Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. ([`pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd`](#source-pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd))

#### Summary

PubMed lists PMID 32091668 in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd`](#source-pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd))

#### Paragraph 1

PubMed lists PMID 32091668 in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd`](#source-pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd`](#source-pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd))

### Sources

<a id="source-pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd"></a>
- **Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. · retained source version 1:2021-08-09:current:6149fb3e80dd6e61f07f8ac429b84ab5872e0c3438b7825a160e9cb35d4a9fda** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32091668/) (`pubmed-observation-pmid-32091668-2021-08-09-6149fb3e80dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Meta-analysis of bivalirudin versus heparin in transradial coronary interventions." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-32091668-bivalirudin-v1 SHA-256: 4ef05b510eb06886df4ef446d768d82e6c03752d19398c7bec9d7f80992de5a6.

---

<a id="pubmed-pmid-32127273-bivalirudin-v1"></a>

## The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

> PubMed lists PMID 32127273 in Journal of cardiothoracic and vascular anesthesia as Journal Article, Review, with publication-date metadata of 2020-01-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32127273-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-08-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32127273-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-32127273-bivalirudin-v1
- Content SHA-256: `3481fe21fd330ffdb197a9c39730b97cdf2d256b365b7405e961a00a26c81813`

### Claims and source pins

#### Headline

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite. ([`pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e`](#source-pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e))

#### Summary

PubMed lists PMID 32127273 in Journal of cardiothoracic and vascular anesthesia as Journal Article, Review, with publication-date metadata of 2020-01-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e`](#source-pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e))

#### Paragraph 1

PubMed lists PMID 32127273 in Journal of cardiothoracic and vascular anesthesia as Journal Article, Review, with publication-date metadata of 2020-01-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e`](#source-pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e`](#source-pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e))

### Sources

<a id="source-pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e"></a>
- **The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite. · retained source version 1:2021-08-02:current:9d6c49c9ba0ef2cd86d81eca8bd263dd8c6b3c37f6c93562a277fa564d2011eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32127273/) (`pubmed-observation-pmid-32127273-2021-08-02-9d6c49c9ba0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-32127273-bivalirudin-v1 SHA-256: 3481fe21fd330ffdb197a9c39730b97cdf2d256b365b7405e961a00a26c81813.

---

<a id="pubmed-pmid-32216471-bivalirudin-v1"></a>

## Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial.

> PubMed lists PMID 32216471 in Circulation. Cardiovascular interventions as Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32216471-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32216471-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-32216471-bivalirudin-v1
- Content SHA-256: `281d8be7e0cb2d9041dcf876170c54bd2551caec065d45281db410472c8e50e6`

### Claims and source pins

#### Headline

Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial. ([`pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0`](#source-pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0))

#### Summary

PubMed lists PMID 32216471 in Circulation. Cardiovascular interventions as Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0`](#source-pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0))

#### Paragraph 1

PubMed lists PMID 32216471 in Circulation. Cardiovascular interventions as Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0`](#source-pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0`](#source-pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0))

### Sources

<a id="source-pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0"></a>
- **Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial. · retained source version 1:2020-11-09:current:f1be5a81a3c0c0545342d549162a97be793529c54a8dbce1c985bb982fa39363** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32216471/) (`pubmed-observation-pmid-32216471-2020-11-09-f1be5a81a3c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-32216471-bivalirudin-v1 SHA-256: 281d8be7e0cb2d9041dcf876170c54bd2551caec065d45281db410472c8e50e6.

---

<a id="pubmed-pmid-33174088-bivalirudin-v1"></a>

## A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support.

> PubMed lists PMID 33174088 in American journal of cardiovascular drugs : drugs, devices, and other interventions as Journal Article, Review, with publication-date metadata of 2020-11-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33174088-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33174088-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-33174088-bivalirudin-v1
- Content SHA-256: `da19015c9974dd06634e5b841fa54b9ebd4845fc5f13fe309212211dce522f79`

### Claims and source pins

#### Headline

A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support. ([`pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973`](#source-pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973))

#### Summary

PubMed lists PMID 33174088 in American journal of cardiovascular drugs : drugs, devices, and other interventions as Journal Article, Review, with publication-date metadata of 2020-11-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973`](#source-pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973))

#### Paragraph 1

PubMed lists PMID 33174088 in American journal of cardiovascular drugs : drugs, devices, and other interventions as Journal Article, Review, with publication-date metadata of 2020-11-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973`](#source-pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973`](#source-pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973))

### Sources

<a id="source-pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973"></a>
- **A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support. · retained source version 1:2021-12-14:current:9ea2a797597301d47123f8b6b320727cb56f76a4730506d589b1bbb97ad4df0b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33174088/) (`pubmed-observation-pmid-33174088-2021-12-14-9ea2a7975973`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-33174088-bivalirudin-v1 SHA-256: da19015c9974dd06634e5b841fa54b9ebd4845fc5f13fe309212211dce522f79.

---

<a id="pubmed-pmid-34491323-bivalirudin-v1"></a>

## Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial.

> PubMed lists PMID 34491323 in European heart journal. Acute cardiovascular care as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2021-12-18 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34491323-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34491323-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-34491323-bivalirudin-v1
- Content SHA-256: `c516042f99ca236586fba80aad21a98f5ce698de12a8ddafe02216bc1deec74f`

### Claims and source pins

#### Headline

Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. ([`pubmed-observation-pmid-34491323-2021-12-21-825583d99edb`](#source-pubmed-observation-pmid-34491323-2021-12-21-825583d99edb))

#### Summary

PubMed lists PMID 34491323 in European heart journal. Acute cardiovascular care as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2021-12-18 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34491323-2021-12-21-825583d99edb`](#source-pubmed-observation-pmid-34491323-2021-12-21-825583d99edb))

#### Paragraph 1

PubMed lists PMID 34491323 in European heart journal. Acute cardiovascular care as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2021-12-18 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34491323-2021-12-21-825583d99edb`](#source-pubmed-observation-pmid-34491323-2021-12-21-825583d99edb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34491323-2021-12-21-825583d99edb`](#source-pubmed-observation-pmid-34491323-2021-12-21-825583d99edb))

### Sources

<a id="source-pubmed-observation-pmid-34491323-2021-12-21-825583d99edb"></a>
- **Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. · retained source version 1:2021-12-21:current:825583d99edbf57266bf44cb22fbef4414d1ea394aca98b0556d9fe108d231a9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34491323/) (`pubmed-observation-pmid-34491323-2021-12-21-825583d99edb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-34491323-bivalirudin-v1 SHA-256: c516042f99ca236586fba80aad21a98f5ce698de12a8ddafe02216bc1deec74f.

---

<a id="pubmed-pmid-35007937-bivalirudin-v1"></a>

## Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis.

> PubMed lists PMID 35007937 in Thrombosis research as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-12-31 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35007937-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35007937-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35007937-bivalirudin-v1
- Content SHA-256: `8c449b0727850112ab4e721a488c72431da60f6e50fe5cd8b328e715db0a6c3c`

### Claims and source pins

#### Headline

Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis. ([`pubmed-observation-pmid-35007937-2022-04-01-d895045f9899`](#source-pubmed-observation-pmid-35007937-2022-04-01-d895045f9899))

#### Summary

PubMed lists PMID 35007937 in Thrombosis research as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-12-31 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35007937-2022-04-01-d895045f9899`](#source-pubmed-observation-pmid-35007937-2022-04-01-d895045f9899))

#### Paragraph 1

PubMed lists PMID 35007937 in Thrombosis research as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-12-31 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35007937-2022-04-01-d895045f9899`](#source-pubmed-observation-pmid-35007937-2022-04-01-d895045f9899))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35007937-2022-04-01-d895045f9899`](#source-pubmed-observation-pmid-35007937-2022-04-01-d895045f9899))

### Sources

<a id="source-pubmed-observation-pmid-35007937-2022-04-01-d895045f9899"></a>
- **Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis. · retained source version 1:2022-04-01:current:d895045f9899466c91d7290e7f5558ee273ec9c6551aae6fe79a8f4d48a9ffe9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35007937/) (`pubmed-observation-pmid-35007937-2022-04-01-d895045f9899`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35007937-bivalirudin-v1 SHA-256: 8c449b0727850112ab4e721a488c72431da60f6e50fe5cd8b328e715db0a6c3c.

---

<a id="pubmed-pmid-35065202-bivalirudin-v1"></a>

## Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis.

> PubMed lists PMID 35065202 in Pharmacological research as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2022-01-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35065202-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35065202-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35065202-bivalirudin-v1
- Content SHA-256: `3d62db9cd8d63711b8af29c9aec265516f822038c43ee332a1eea8fb005c1892`

### Claims and source pins

#### Headline

Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis. ([`pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3`](#source-pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3))

#### Summary

PubMed lists PMID 35065202 in Pharmacological research as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2022-01-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3`](#source-pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3))

#### Paragraph 1

PubMed lists PMID 35065202 in Pharmacological research as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2022-01-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3`](#source-pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3`](#source-pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3))

### Sources

<a id="source-pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3"></a>
- **Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis. · retained source version 1:2026-11-09:current:b532a4422ad3c7ae5f1eec365f5ba3c8b6a29472d29ac1d9e0b443f5a334f12e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35065202/) (`pubmed-observation-pmid-35065202-2026-11-09-b532a4422ad3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35065202-bivalirudin-v1 SHA-256: 3d62db9cd8d63711b8af29c9aec265516f822038c43ee332a1eea8fb005c1892.

---

<a id="pubmed-pmid-35098565-bivalirudin-v1"></a>

## Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis.

> PubMed lists PMID 35098565 in British journal of clinical pharmacology as Journal Article, Meta-Analysis, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35098565-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35098565-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35098565-bivalirudin-v1
- Content SHA-256: `957f452cf1e74b391b643ca26f527eecfceadaffc2a6f1d21963f997e9a7ea8b`

### Claims and source pins

#### Headline

Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis. ([`pubmed-observation-pmid-35098565-2026-11-09-9034e783286e`](#source-pubmed-observation-pmid-35098565-2026-11-09-9034e783286e))

#### Summary

PubMed lists PMID 35098565 in British journal of clinical pharmacology as Journal Article, Meta-Analysis, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35098565-2026-11-09-9034e783286e`](#source-pubmed-observation-pmid-35098565-2026-11-09-9034e783286e))

#### Paragraph 1

PubMed lists PMID 35098565 in British journal of clinical pharmacology as Journal Article, Meta-Analysis, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35098565-2026-11-09-9034e783286e`](#source-pubmed-observation-pmid-35098565-2026-11-09-9034e783286e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35098565-2026-11-09-9034e783286e`](#source-pubmed-observation-pmid-35098565-2026-11-09-9034e783286e))

### Sources

<a id="source-pubmed-observation-pmid-35098565-2026-11-09-9034e783286e"></a>
- **Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis. · retained source version 1:2026-11-09:current:9034e783286e98e07dd09211b106fb70f0a6927e103c823ee27626948aebec69** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35098565/) (`pubmed-observation-pmid-35098565-2026-11-09-9034e783286e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35098565-bivalirudin-v1 SHA-256: 957f452cf1e74b391b643ca26f527eecfceadaffc2a6f1d21963f997e9a7ea8b.

---

<a id="pubmed-pmid-35616224-bivalirudin-v1"></a>

## Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation.

> PubMed lists PMID 35616224 in Perfusion as Journal Article, Meta-Analysis, with publication-date metadata of 2022-05-26 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35616224-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35616224-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35616224-bivalirudin-v1
- Content SHA-256: `3fb5a5841b2a7b87bd32b5dcd4c05c96821fe64f5918f7862c033d673ffd1ef0`

### Claims and source pins

#### Headline

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation. ([`pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0`](#source-pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0))

#### Summary

PubMed lists PMID 35616224 in Perfusion as Journal Article, Meta-Analysis, with publication-date metadata of 2022-05-26 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0`](#source-pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0))

#### Paragraph 1

PubMed lists PMID 35616224 in Perfusion as Journal Article, Meta-Analysis, with publication-date metadata of 2022-05-26 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0`](#source-pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0`](#source-pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0))

### Sources

<a id="source-pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0"></a>
- **Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation. · retained source version 1:2026-11-09:current:c0836fd32be0e1013334b14d5892b7cb0a177620fa22ccb7c427280dc270ddfd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35616224/) (`pubmed-observation-pmid-35616224-2026-11-09-c0836fd32be0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35616224-bivalirudin-v1 SHA-256: 3fb5a5841b2a7b87bd32b5dcd4c05c96821fe64f5918f7862c033d673ffd1ef0.

---

<a id="pubmed-pmid-35634698-bivalirudin-v1"></a>

## Bivalirudin in pediatric extracorporeal membrane oxygenation.

> PubMed lists PMID 35634698 in Current opinion in pediatrics as Journal Article, Review, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35634698-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-06-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35634698-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35634698-bivalirudin-v1
- Content SHA-256: `4cb88a34458eb806a017e3a559c422e0aba1c8e86e94e5d65e40316fa0f6dd96`

### Claims and source pins

#### Headline

Bivalirudin in pediatric extracorporeal membrane oxygenation. ([`pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0`](#source-pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0))

#### Summary

PubMed lists PMID 35634698 in Current opinion in pediatrics as Journal Article, Review, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0`](#source-pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0))

#### Paragraph 1

PubMed lists PMID 35634698 in Current opinion in pediatrics as Journal Article, Review, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0`](#source-pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0`](#source-pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0))

### Sources

<a id="source-pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0"></a>
- **Bivalirudin in pediatric extracorporeal membrane oxygenation. · retained source version 1:2022-06-07:current:a98dc927c4f0cd76f5123e424fcea4b0713503c4cd16ac6815bbe8ff03cbb74a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35634698/) (`pubmed-observation-pmid-35634698-2022-06-07-a98dc927c4f0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin in pediatric extracorporeal membrane oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-35634698-bivalirudin-v1 SHA-256: 4cb88a34458eb806a017e3a559c422e0aba1c8e86e94e5d65e40316fa0f6dd96.

---

<a id="pubmed-pmid-36194483-bivalirudin-v1"></a>

## Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation.

> PubMed lists PMID 36194483 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Systematic Review, Meta-Analysis, Journal Article, with publication-date metadata of 2022-04-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36194483-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-04-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36194483-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36194483-bivalirudin-v1
- Content SHA-256: `a0e3886d233336c5f1bb72777c0fc304b8fe45b41928d4ce14071b2434b68fd6`

### Claims and source pins

#### Headline

Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation. ([`pubmed-observation-pmid-36194483-2023-04-18-a1a683723721`](#source-pubmed-observation-pmid-36194483-2023-04-18-a1a683723721))

#### Summary

PubMed lists PMID 36194483 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Systematic Review, Meta-Analysis, Journal Article, with publication-date metadata of 2022-04-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36194483-2023-04-18-a1a683723721`](#source-pubmed-observation-pmid-36194483-2023-04-18-a1a683723721))

#### Paragraph 1

PubMed lists PMID 36194483 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Systematic Review, Meta-Analysis, Journal Article, with publication-date metadata of 2022-04-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36194483-2023-04-18-a1a683723721`](#source-pubmed-observation-pmid-36194483-2023-04-18-a1a683723721))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36194483-2023-04-18-a1a683723721`](#source-pubmed-observation-pmid-36194483-2023-04-18-a1a683723721))

### Sources

<a id="source-pubmed-observation-pmid-36194483-2023-04-18-a1a683723721"></a>
- **Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation. · retained source version 1:2023-04-18:current:a1a683723721c00f905c941cf3fe5f249d022c7ab40f2eb0c3eac00a0df4e6de** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36194483/) (`pubmed-observation-pmid-36194483-2023-04-18-a1a683723721`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36194483-bivalirudin-v1 SHA-256: a0e3886d233336c5f1bb72777c0fc304b8fe45b41928d4ce14071b2434b68fd6.

---

<a id="pubmed-pmid-36355803-bivalirudin-v1"></a>

## Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 36355803 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Meta-Analysis, Systematic Review, Journal Article, with publication-date metadata of 2022-11-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36355803-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36355803-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36355803-bivalirudin-v1
- Content SHA-256: `58a7b2de50cf76ca4cde3baa5a31adb5a093319a690b5b5923601164414c0e9e`

### Claims and source pins

#### Headline

Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19`](#source-pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19))

#### Summary

PubMed lists PMID 36355803 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Meta-Analysis, Systematic Review, Journal Article, with publication-date metadata of 2022-11-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19`](#source-pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19))

#### Paragraph 1

PubMed lists PMID 36355803 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Meta-Analysis, Systematic Review, Journal Article, with publication-date metadata of 2022-11-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19`](#source-pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19`](#source-pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19))

### Sources

<a id="source-pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19"></a>
- **Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. · retained source version 1:2026-11-09:current:b73a75f3ed1968d0fac55da90714cde79932ba75a8ed52524b81dee6e22bb6a7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36355803/) (`pubmed-observation-pmid-36355803-2026-11-09-b73a75f3ed19`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36355803-bivalirudin-v1 SHA-256: 58a7b2de50cf76ca4cde3baa5a31adb5a093319a690b5b5923601164414c0e9e.

---

<a id="pubmed-pmid-36449392-bivalirudin-v1"></a>

## Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation.

> PubMed lists PMID 36449392 in Journal of pharmacy practice as Meta-Analysis, Journal Article, with publication-date metadata of 2022-11-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36449392-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36449392-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36449392-bivalirudin-v1
- Content SHA-256: `9b3774dee5cf0a7b112bda16d0473057e26a9bd3ce4dd95eb37b3db565b417de`

### Claims and source pins

#### Headline

Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation. ([`pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e`](#source-pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e))

#### Summary

PubMed lists PMID 36449392 in Journal of pharmacy practice as Meta-Analysis, Journal Article, with publication-date metadata of 2022-11-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e`](#source-pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e))

#### Paragraph 1

PubMed lists PMID 36449392 in Journal of pharmacy practice as Meta-Analysis, Journal Article, with publication-date metadata of 2022-11-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e`](#source-pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e`](#source-pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e))

### Sources

<a id="source-pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e"></a>
- **Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation. · retained source version 1:2026-11-09:current:9d6aa461370ec5361e6574bbddb2eb7d53f1d8398e84c2bf28e806185874f8cd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36449392/) (`pubmed-observation-pmid-36449392-2026-11-09-9d6aa461370e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36449392-bivalirudin-v1 SHA-256: 9b3774dee5cf0a7b112bda16d0473057e26a9bd3ce4dd95eb37b3db565b417de.

---

<a id="pubmed-pmid-36999064-bivalirudin-v1"></a>

## Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review.

> PubMed lists PMID 36999064 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2023-03-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36999064-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-04-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36999064-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36999064-bivalirudin-v1
- Content SHA-256: `e7b6df9ad73d4699b64ccb43443a397294696d2d7a740ec5e06a5ae1433bb0ab`

### Claims and source pins

#### Headline

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review. ([`pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9`](#source-pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9))

#### Summary

PubMed lists PMID 36999064 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2023-03-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9`](#source-pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9))

#### Paragraph 1

PubMed lists PMID 36999064 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2023-03-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9`](#source-pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9`](#source-pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9))

### Sources

<a id="source-pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9"></a>
- **Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review. · retained source version 1:2023-04-01:current:8d887f39d2c9e322d53b3d02f044f8034012f5997a6e9d4fd742e62abef7957e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36999064/) (`pubmed-observation-pmid-36999064-2023-04-01-8d887f39d2c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-36999064-bivalirudin-v1 SHA-256: e7b6df9ad73d4699b64ccb43443a397294696d2d7a740ec5e06a5ae1433bb0ab.

---

<a id="pubmed-pmid-37671395-bivalirudin-v1"></a>

## Is it time to switch to bivalirudin for ECMO anticoagulation?

> PubMed lists PMID 37671395 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37671395-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37671395-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-37671395-bivalirudin-v1
- Content SHA-256: `835662e98f91ff090584187a3fd13eb5effff4fc6d46e53d0b37d878a6860452`

### Claims and source pins

#### Headline

Is it time to switch to bivalirudin for ECMO anticoagulation? ([`pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41`](#source-pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41))

#### Summary

PubMed lists PMID 37671395 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41`](#source-pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41))

#### Paragraph 1

PubMed lists PMID 37671395 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41`](#source-pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41`](#source-pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41))

### Sources

<a id="source-pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41"></a>
- **Is it time to switch to bivalirudin for ECMO anticoagulation? · retained source version 1:2023-09-07:current:d66cc0ecbc41a2aa9b601b2cfdd7c070ec582207c3068a088f0f5124a6f46bd1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37671395/) (`pubmed-observation-pmid-37671395-2023-09-07-d66cc0ecbc41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Is it time to switch to bivalirudin for ECMO anticoagulation?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-37671395-bivalirudin-v1 SHA-256: 835662e98f91ff090584187a3fd13eb5effff4fc6d46e53d0b37d878a6860452.

---

<a id="pubmed-pmid-37746717-bivalirudin-v1"></a>

## Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.

> PubMed lists PMID 37746717 in Circulation as Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37746717-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-11-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37746717-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-37746717-bivalirudin-v1
- Content SHA-256: `91fd3423a8fa0d9fa9c34ab818fa4d0a295c1860d25b802e347b513ae83bf4ed`

### Claims and source pins

#### Headline

Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. ([`pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff`](#source-pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff))

#### Summary

PubMed lists PMID 37746717 in Circulation as Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff`](#source-pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff))

#### Paragraph 1

PubMed lists PMID 37746717 in Circulation as Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff`](#source-pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff`](#source-pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff))

### Sources

<a id="source-pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff"></a>
- **Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. · retained source version 1:2023-11-07:current:5d4829fbf6ffa906ad8ec16b767b528d2b35eb929f7ca4632cc3d56a9cf18230** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37746717/) (`pubmed-observation-pmid-37746717-2023-11-07-5d4829fbf6ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-37746717-bivalirudin-v1 SHA-256: 91fd3423a8fa0d9fa9c34ab818fa4d0a295c1860d25b802e347b513ae83bf4ed.

---

<a id="pubmed-pmid-37865864-bivalirudin-v1"></a>

## Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.

> PubMed lists PMID 37865864 in Coronary artery disease as Meta-Analysis, Journal Article, with publication-date metadata of 2023-09-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37865864-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37865864-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-37865864-bivalirudin-v1
- Content SHA-256: `b8d1cac3bb2aba1bc9ba6855e839d423821cdbe3a9c45ce5530ce8d4517bf518`

### Claims and source pins

#### Headline

Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis. ([`pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053`](#source-pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053))

#### Summary

PubMed lists PMID 37865864 in Coronary artery disease as Meta-Analysis, Journal Article, with publication-date metadata of 2023-09-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053`](#source-pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053))

#### Paragraph 1

PubMed lists PMID 37865864 in Coronary artery disease as Meta-Analysis, Journal Article, with publication-date metadata of 2023-09-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053`](#source-pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053`](#source-pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053))

### Sources

<a id="source-pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053"></a>
- **Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis. · retained source version 1:2026-11-09:current:a3627cb5905381d687d03e34253d59aa50ab453a544111a7a179e5379b6fc5f9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37865864/) (`pubmed-observation-pmid-37865864-2026-11-09-a3627cb59053`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-37865864-bivalirudin-v1 SHA-256: b8d1cac3bb2aba1bc9ba6855e839d423821cdbe3a9c45ce5530ce8d4517bf518.

---

<a id="pubmed-pmid-38084653-bivalirudin-v1"></a>

## Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery.

> PubMed lists PMID 38084653 in Perfusion as Journal Article, Review, with publication-date metadata of 2023-12-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38084653-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38084653-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-38084653-bivalirudin-v1
- Content SHA-256: `4ff34fa727294e33c378f7c163924a349f1746ed5bfec3302e1de12d32772eb2`

### Claims and source pins

#### Headline

Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery. ([`pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d`](#source-pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d))

#### Summary

PubMed lists PMID 38084653 in Perfusion as Journal Article, Review, with publication-date metadata of 2023-12-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d`](#source-pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d))

#### Paragraph 1

PubMed lists PMID 38084653 in Perfusion as Journal Article, Review, with publication-date metadata of 2023-12-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d`](#source-pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d`](#source-pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d))

### Sources

<a id="source-pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d"></a>
- **Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery. · retained source version 1:2026-05-07:current:6ef7833e623dd4f4ba133876eb942166a162382cc713564f31bcaa1ad07c63d1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38084653/) (`pubmed-observation-pmid-38084653-2026-05-07-6ef7833e623d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-38084653-bivalirudin-v1 SHA-256: 4ff34fa727294e33c378f7c163924a349f1746ed5bfec3302e1de12d32772eb2.

---

<a id="pubmed-pmid-39259286-bivalirudin-v1"></a>

## Bivalirudin in Extracorporeal Membrane Oxygenation.

> PubMed lists PMID 39259286 in Journal of cardiovascular pharmacology as Journal Article, Review, with publication-date metadata of 2024-12-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39259286-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39259286-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-39259286-bivalirudin-v1
- Content SHA-256: `cec3ca8b4ca839e6eb3cef3a6a080f0b056870c8af26fdcdf0ddddcf3375adb4`

### Claims and source pins

#### Headline

Bivalirudin in Extracorporeal Membrane Oxygenation. ([`pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6`](#source-pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6))

#### Summary

PubMed lists PMID 39259286 in Journal of cardiovascular pharmacology as Journal Article, Review, with publication-date metadata of 2024-12-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6`](#source-pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6))

#### Paragraph 1

PubMed lists PMID 39259286 in Journal of cardiovascular pharmacology as Journal Article, Review, with publication-date metadata of 2024-12-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6`](#source-pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6`](#source-pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6))

### Sources

<a id="source-pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6"></a>
- **Bivalirudin in Extracorporeal Membrane Oxygenation. · retained source version 1:2026-11-09:current:d8b8bbd7bdf63cd1c54a8efcd0144447eff6f8088b83658860a87782f00d1e18** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39259286/) (`pubmed-observation-pmid-39259286-2026-11-09-d8b8bbd7bdf6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin in Extracorporeal Membrane Oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-39259286-bivalirudin-v1 SHA-256: cec3ca8b4ca839e6eb3cef3a6a080f0b056870c8af26fdcdf0ddddcf3375adb4.

---

<a id="pubmed-pmid-39334129-bivalirudin-v1"></a>

## Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial.

> PubMed lists PMID 39334129 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-09-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39334129-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39334129-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-39334129-bivalirudin-v1
- Content SHA-256: `9a435aa17f02cc5cdc0b63b33aa830bbe68d9867f34ef824292a79d58f646037`

### Claims and source pins

#### Headline

Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial. ([`pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a`](#source-pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a))

#### Summary

PubMed lists PMID 39334129 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-09-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a`](#source-pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a))

#### Paragraph 1

PubMed lists PMID 39334129 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-09-27 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a`](#source-pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a`](#source-pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a))

### Sources

<a id="source-pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a"></a>
- **Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial. · retained source version 1:2024-12-03:current:040cabd6072a07734e3fb8f9ccb78b287134c5202da5eb5e7d52bab750b4e732** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39334129/) (`pubmed-observation-pmid-39334129-2024-12-03-040cabd6072a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-39334129-bivalirudin-v1 SHA-256: 9a435aa17f02cc5cdc0b63b33aa830bbe68d9867f34ef824292a79d58f646037.

---

<a id="pubmed-pmid-39585174-bivalirudin-v1"></a>

## Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.

> PubMed lists PMID 39585174 in Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39585174-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39585174-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-39585174-bivalirudin-v1
- Content SHA-256: `1e485e268c2d0d994f4ea4030f303fda07faf8e13d81678aacf9edb509a4a9da`

### Claims and source pins

#### Headline

Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation. ([`pubmed-observation-pmid-39585174-2026-11-09-112283fc425c`](#source-pubmed-observation-pmid-39585174-2026-11-09-112283fc425c))

#### Summary

PubMed lists PMID 39585174 in Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39585174-2026-11-09-112283fc425c`](#source-pubmed-observation-pmid-39585174-2026-11-09-112283fc425c))

#### Paragraph 1

PubMed lists PMID 39585174 in Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39585174-2026-11-09-112283fc425c`](#source-pubmed-observation-pmid-39585174-2026-11-09-112283fc425c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39585174-2026-11-09-112283fc425c`](#source-pubmed-observation-pmid-39585174-2026-11-09-112283fc425c))

### Sources

<a id="source-pubmed-observation-pmid-39585174-2026-11-09-112283fc425c"></a>
- **Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation. · retained source version 1:2026-11-09:current:112283fc425c265679202a06db1d697db4e6f0b259fb61c45ea2089ae25297c6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39585174/) (`pubmed-observation-pmid-39585174-2026-11-09-112283fc425c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-39585174-bivalirudin-v1 SHA-256: 1e485e268c2d0d994f4ea4030f303fda07faf8e13d81678aacf9edb509a4a9da.

---

<a id="pubmed-pmid-40436723-bivalirudin-v1"></a>

## Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial.

> PubMed lists PMID 40436723 in Cardiovascular revascularization medicine : including molecular interventions as Journal Article, Comparative Study, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-05-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40436723-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40436723-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-40436723-bivalirudin-v1
- Content SHA-256: `19311573b7d72170467c71ac83de26836e18b1e6e9bc6ea9fc92df1f09b74db6`

### Claims and source pins

#### Headline

Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial. ([`pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171`](#source-pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171))

#### Summary

PubMed lists PMID 40436723 in Cardiovascular revascularization medicine : including molecular interventions as Journal Article, Comparative Study, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-05-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171`](#source-pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171))

#### Paragraph 1

PubMed lists PMID 40436723 in Cardiovascular revascularization medicine : including molecular interventions as Journal Article, Comparative Study, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-05-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171`](#source-pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171`](#source-pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171))

### Sources

<a id="source-pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171"></a>
- **Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial. · retained source version 1:2026-05-22:current:bee8869c01716f113d554666750b6aed96d1cbbaba250e6a90ee37da004c6a11** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40436723/) (`pubmed-observation-pmid-40436723-2026-05-22-bee8869c0171`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-40436723-bivalirudin-v1 SHA-256: 19311573b7d72170467c71ac83de26836e18b1e6e9bc6ea9fc92df1f09b74db6.

---

<a id="pubmed-pmid-41029353-bivalirudin-v1"></a>

## BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis.

> PubMed lists PMID 41029353 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2025-09-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41029353-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-11-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41029353-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-41029353-bivalirudin-v1
- Content SHA-256: `b2489488041672abf8d824d75b0eae5f148d9cff2a852fd7c3bff16809b30316`

### Claims and source pins

#### Headline

BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis. ([`pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2`](#source-pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2))

#### Summary

PubMed lists PMID 41029353 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2025-09-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2`](#source-pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2))

#### Paragraph 1

PubMed lists PMID 41029353 in BMC medicine as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2025-09-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2`](#source-pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2`](#source-pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2))

### Sources

<a id="source-pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2"></a>
- **BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis. · retained source version 1:2025-11-24:current:7e96362ba6b2eb07841998c86c2107e9fc321d7441e0fca1ac1786686c38cd5f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41029353/) (`pubmed-observation-pmid-41029353-2025-11-24-7e96362ba6b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-41029353-bivalirudin-v1 SHA-256: b2489488041672abf8d824d75b0eae5f148d9cff2a852fd7c3bff16809b30316.

---

<a id="pubmed-pmid-42602128-bivalirudin-v1"></a>

## Bivalirudin as an Alternative to Heparin in Pediatric Cardiac Procedures: Evidence, Challenges, and Future Directions.

> PubMed lists PMID 42602128 in Sage open pediatrics as Journal Article, Review, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42602128-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42602128-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-42602128-bivalirudin-v1
- Content SHA-256: `2d7a1ae2da37c007e71b9d5a2d785cdf0ef0bf36f689dccb2d4be349d269d3cf`

### Claims and source pins

#### Headline

Bivalirudin as an Alternative to Heparin in Pediatric Cardiac Procedures: Evidence, Challenges, and Future Directions. ([`pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8`](#source-pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8))

#### Summary

PubMed lists PMID 42602128 in Sage open pediatrics as Journal Article, Review, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8`](#source-pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8))

#### Paragraph 1

PubMed lists PMID 42602128 in Sage open pediatrics as Journal Article, Review, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8`](#source-pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8`](#source-pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8))

### Sources

<a id="source-pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8"></a>
- **Bivalirudin as an Alternative to Heparin in Pediatric Cardiac Procedures: Evidence, Challenges, and Future Directions. · retained source version 1:2026-08-16:current:dec21f98daf8fb68b267ad92cba00420209e8e869e159cff49856677d29f6c69** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42602128/) (`pubmed-observation-pmid-42602128-2026-08-16-dec21f98daf8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin as an Alternative to Heparin in Pediatric Cardiac Procedures: Evidence, Challenges, and Future Directions." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-42602128-bivalirudin-v1 SHA-256: 2d7a1ae2da37c007e71b9d5a2d785cdf0ef0bf36f689dccb2d4be349d269d3cf.

---

<a id="pubmed-pmid-42862663-bivalirudin-v1"></a>

## Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 42862663 in Annals of cardiac anaesthesia as Journal Article, Systematic Review, Meta-Analysis, Comparative Study, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42862663-bivalirudin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42862663-bivalirudin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-42862663-bivalirudin-v1
- Content SHA-256: `e8564e23f998fdaff6d33a7cb375ac74013c49d8f99e34891491defacc45889a`

### Claims and source pins

#### Headline

Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d`](#source-pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d))

#### Summary

PubMed lists PMID 42862663 in Annals of cardiac anaesthesia as Journal Article, Systematic Review, Meta-Analysis, Comparative Study, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d`](#source-pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d))

#### Paragraph 1

PubMed lists PMID 42862663 in Annals of cardiac anaesthesia as Journal Article, Systematic Review, Meta-Analysis, Comparative Study, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d`](#source-pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d`](#source-pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d))

### Sources

<a id="source-pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d"></a>
- **Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis. · retained source version 1:2026-11-08:current:782762ec4d0db579d0ad4b7e15518feaf2da76a8ed5edd11e1904f9ba59d031c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42862663/) (`pubmed-observation-pmid-42862663-2026-11-08-782762ec4d0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/bivalirudin.json#pubmed-pmid-42862663-bivalirudin-v1 SHA-256: e8564e23f998fdaff6d33a7cb375ac74013c49d8f99e34891491defacc45889a.

